US7291331B1
(en)
|
2002-09-11 |
2007-11-06 |
La Jolla Institute For Allergy And Immunology |
Methods of treating OX40 medicated recall immune responses
|
JP5620626B2
(ja)
|
2005-03-31 |
2014-11-05 |
中外製薬株式会社 |
会合制御によるポリペプチド製造方法
|
BRPI0613361A2
(pt)
|
2005-07-01 |
2011-01-04 |
Medarex Inc |
anticorpo monoclonal humano isolado, composição, imunoconjugado, molécula biespecìfica, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, camundongo transgênico, método para modular uma resposta imune num indivìduo, método para inibir crescimento de células tumorais num indivìduo, método para tratar uma doença infecciosa num indivìduo, método para aumentar uma resposta imune a um antìgeno num indivìduo, método para tratar ou prevenir uma doença inflamatória num indivìduo e método para preparar o anticorpo anti-pd-l1
|
CA2633602A1
(en)
*
|
2005-12-16 |
2007-11-22 |
Genentech, Inc. |
Anti-ox40l antibodies and methods using same
|
DK3056568T3
(da)
|
2006-03-31 |
2021-11-01 |
Chugai Pharmaceutical Co Ltd |
Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik
|
EP3345616A1
(en)
|
2006-03-31 |
2018-07-11 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody modification method for purifying bispecific antibody
|
WO2008011348A2
(en)
|
2006-07-14 |
2008-01-24 |
Ac Immune S.A. |
Humanized antibody against amyloid beta
|
HUE052220T2
(hu)
*
|
2006-09-08 |
2021-04-28 |
Abbvie Bahamas Ltd |
Interleukin-13 kötõfehérjék
|
JP2010528583A
(ja)
*
|
2007-06-11 |
2010-08-26 |
エーシー イミューン ソシエテ アノニム |
アミロイドβに対するヒト化抗体
|
US8048420B2
(en)
|
2007-06-12 |
2011-11-01 |
Ac Immune S.A. |
Monoclonal antibody
|
US8613923B2
(en)
|
2007-06-12 |
2013-12-24 |
Ac Immune S.A. |
Monoclonal antibody
|
JP5334319B2
(ja)
|
2007-09-26 |
2013-11-06 |
中外製薬株式会社 |
Cdrのアミノ酸置換により抗体の等電点を改変する方法
|
SG193868A1
(en)
|
2007-09-26 |
2013-10-30 |
Chugai Pharmaceutical Co Ltd |
Modified antibody constant region
|
PT2238166E
(pt)
|
2007-10-05 |
2014-02-11 |
Genentech Inc |
Utilização do anticorpo anti-amilóide beta em doenças oculares
|
WO2009141239A1
(en)
*
|
2008-05-20 |
2009-11-26 |
F. Hoffmann-La Roche Ag |
A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
|
WO2010062960A2
(en)
|
2008-11-26 |
2010-06-03 |
Cedars-Sinai Medical Center |
METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
|
PT2398498T
(pt)
|
2009-02-17 |
2018-12-03 |
Ucb Biopharma Sprl |
Moléculas de anticorpo tendo especificidade para ox40 humano
|
TWI544077B
(zh)
|
2009-03-19 |
2016-08-01 |
Chugai Pharmaceutical Co Ltd |
Antibody constant region change body
|
EP2409991B1
(en)
|
2009-03-19 |
2017-05-03 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
ES2572728T3
(es)
|
2009-03-20 |
2016-06-02 |
F. Hoffmann-La Roche Ag |
Anticuerpos anti-HER biespecíficos
|
DK2411411T3
(en)
|
2009-03-25 |
2016-11-07 |
Hoffmann La Roche |
New anti-alpha5beta1 antibodies and uses thereof
|
US20100256340A1
(en)
|
2009-04-07 |
2010-10-07 |
Ulrich Brinkmann |
Trivalent, bispecific antibodies
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
JP5837821B2
(ja)
|
2009-09-24 |
2015-12-24 |
中外製薬株式会社 |
抗体定常領域改変体
|
EP3309176A1
(en)
|
2009-12-14 |
2018-04-18 |
Ablynx N.V. |
Immunoglobulin single variable domain antibodies against ox40l, constructs and therapeutic use
|
NZ599840A
(en)
|
2009-12-22 |
2014-06-27 |
Hoffmann La Roche |
Sequence dependent aggregation
|
PL2536748T3
(pl)
|
2010-02-18 |
2015-01-30 |
Genentech Inc |
Antagoniści neureguliny i ich zastosowanie w leczeniu nowotworu
|
EP2543730B1
(en)
*
|
2010-03-04 |
2018-10-31 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
SG184033A1
(en)
|
2010-03-24 |
2012-10-30 |
Genentech Inc |
Anti-lrp6 antibodies
|
WO2011147834A1
(en)
|
2010-05-26 |
2011-12-01 |
Roche Glycart Ag |
Antibodies against cd19 and uses thereof
|
WO2011159980A1
(en)
|
2010-06-18 |
2011-12-22 |
Genentech, Inc. |
Anti-axl antibodies and methods of use
|
WO2011161119A1
(en)
|
2010-06-22 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Antibodies against insulin-like growth factor i receptor and uses thereof
|
WO2011161189A1
(en)
|
2010-06-24 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Anti-hepsin antibodies and methods of use
|
EP2399604A1
(en)
|
2010-06-25 |
2011-12-28 |
F. Hoffmann-La Roche AG |
Novel antibody formulation
|
NZ605449A
(en)
|
2010-07-09 |
2015-03-27 |
Genentech Inc |
Anti-neuropilin antibodies and methods of use
|
WO2012010582A1
(en)
|
2010-07-21 |
2012-01-26 |
Roche Glycart Ag |
Anti-cxcr5 antibodies and methods of use
|
RU2607368C2
(ru)
|
2010-07-30 |
2017-01-10 |
Ац Иммуне С.А. |
Безопасные и функциональные гуманизированные антитела
|
WO2012017003A1
(en)
|
2010-08-05 |
2012-02-09 |
F. Hoffmann-La Roche Ag |
Anti-mhc antibody anti-viral cytokine fusion protein
|
KR101653030B1
(ko)
|
2010-08-13 |
2016-08-31 |
로슈 글리카트 아게 |
항-테나신-c a2 항체 및 이의 사용 방법
|
EA034742B1
(ru)
|
2010-08-13 |
2020-03-16 |
Роше Гликарт Аг |
Антитела к fap, полинуклеотид, вектор и клетка для их получения и их применения
|
MY171312A
(en)
|
2010-08-23 |
2019-10-08 |
Univ Texas |
Anti-ox40 antibodies and methods of using the same
|
WO2012025536A1
(en)
|
2010-08-25 |
2012-03-01 |
F. Hoffmann-La Roche Ag |
Antibodies against il-18r1 and uses thereof
|
AU2011326564A1
(en)
|
2010-11-10 |
2013-05-09 |
Genentech, Inc. |
Methods and compositions for neural disease immunotherapy
|
US20150353643A1
(en)
*
|
2013-09-24 |
2015-12-10 |
Universite De La Mediterranee - Aix-Marseille Ii |
Anti-cd277 antibodies and uses thereof
|
US11904004B2
(en)
*
|
2010-12-15 |
2024-02-20 |
Inserm |
Anti-CD277 antibodies
|
WO2012083132A2
(en)
|
2010-12-16 |
2012-06-21 |
Genentech, Inc. |
Diagnosis and treatments relating to th2 inhibition
|
TWI589589B
(zh)
|
2010-12-20 |
2017-07-01 |
建南德克公司 |
抗間皮素(mesothelin)抗體及免疫接合物
|
TW201307391A
(zh)
|
2010-12-22 |
2013-02-16 |
Genentech Inc |
抗-pcsk9抗體及其使用方法
|
CA2860170C
(en)
|
2010-12-22 |
2022-06-14 |
The Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
RU2013139267A
(ru)
|
2011-02-10 |
2015-03-20 |
Рош Гликарт Аг |
Улучшенная иммунотерапия
|
TW201238976A
(en)
*
|
2011-02-23 |
2012-10-01 |
Hoffmann La Roche |
Antibodies against human IL33R and uses thereof
|
EP2681240B1
(en)
|
2011-02-28 |
2017-08-16 |
F. Hoffmann-La Roche AG |
Monovalent antigen binding proteins
|
RU2607038C2
(ru)
|
2011-02-28 |
2017-01-10 |
Ф. Хоффманн-Ля Рош Аг |
Антигенсвязывающие белки
|
CN103476795B
(zh)
|
2011-03-29 |
2016-07-06 |
罗切格利卡特公司 |
抗体Fc变体
|
WO2012138975A1
(en)
|
2011-04-07 |
2012-10-11 |
Genentech, Inc. |
Anti-fgfr4 antibodies and methods of use
|
WO2012146630A1
(en)
|
2011-04-29 |
2012-11-01 |
F. Hoffmann-La Roche Ag |
N-terminal acylated polypeptides, methods for their production and uses thereof
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
CA2833212C
(en)
|
2011-05-12 |
2020-06-09 |
Genentech, Inc. |
Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides
|
PT2710035T
(pt)
|
2011-05-16 |
2017-06-05 |
Hoffmann La Roche |
Agonistas do fgfr1 e métodos de utilização
|
JP6180408B2
(ja)
*
|
2011-06-13 |
2017-08-16 |
アブゲノミクス コーペラティフ ユー.エー. |
抗psgl−1抗体およびその使用
|
EP2721067B1
(en)
|
2011-06-15 |
2019-07-31 |
F.Hoffmann-La Roche Ag |
Anti-human epo receptor antibodies and methods of use
|
CA2835772C
(en)
|
2011-06-22 |
2020-12-01 |
F. Hoffmann-La Roche Ag |
Removal of target cells by circulating virus-specific cytotoxic t-cells using mhc class i comprising complexes
|
WO2013003680A1
(en)
|
2011-06-30 |
2013-01-03 |
Genentech, Inc. |
Anti-c-met antibody formulations
|
WO2013025853A1
(en)
|
2011-08-17 |
2013-02-21 |
Genentech, Inc. |
Neuregulin antibodies and uses thereof
|
RU2562874C1
(ru)
*
|
2011-08-23 |
2015-09-10 |
Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем |
Антитела против ох40 и способы их применения
|
PL2748202T3
(pl)
|
2011-08-23 |
2018-12-31 |
Roche Glycart Ag |
Dwuswoiste cząsteczki wiążące antygen
|
KR20140048292A
(ko)
|
2011-08-23 |
2014-04-23 |
로슈 글리카트 아게 |
항-mcsp 항체
|
WO2013026837A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
CA2837975C
(en)
|
2011-08-23 |
2022-04-05 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
CA2846083A1
(en)
|
2011-09-15 |
2013-03-21 |
Genentech, Inc. |
Methods of promoting differentiation
|
MX2014004074A
(es)
|
2011-10-05 |
2014-06-05 |
Genentech Inc |
Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
|
LT2766393T
(lt)
|
2011-10-14 |
2018-10-10 |
F. Hoffmann-La Roche Ag |
Antikūnai prieš htra1 ir jų naudojimo būdai
|
JP6254087B2
(ja)
|
2011-10-15 |
2017-12-27 |
ジェネンテック, インコーポレイテッド |
癌を治療するためのscd1アンタゴニスト
|
WO2013059531A1
(en)
|
2011-10-20 |
2013-04-25 |
Genentech, Inc. |
Anti-gcgr antibodies and uses thereof
|
MX2014004991A
(es)
|
2011-10-28 |
2014-05-22 |
Genentech Inc |
Combinaciones terapeuticas y metodos para tratar el melanoma.
|
UA112203C2
(uk)
|
2011-11-11 |
2016-08-10 |
Юсб Фарма С.А. |
Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
|
KR20140095096A
(ko)
|
2011-11-21 |
2014-07-31 |
제넨테크, 인크. |
항-c-met 항체의 정제
|
EP2788024A1
(en)
|
2011-12-06 |
2014-10-15 |
F.Hoffmann-La Roche Ag |
Antibody formulation
|
AR089434A1
(es)
|
2011-12-23 |
2014-08-20 |
Genentech Inc |
Procedimiento para preparar formulaciones con alta concentracion de proteinas
|
CN104411717A
(zh)
|
2012-01-09 |
2015-03-11 |
斯克利普斯研究所 |
具有超长cdr3s的人源化抗体
|
CA2863224A1
(en)
|
2012-01-09 |
2013-07-18 |
The Scripps Research Institute |
Ultralong complementarity determining regions and uses thereof
|
WO2013109856A2
(en)
|
2012-01-18 |
2013-07-25 |
Genentech, Inc. |
Methods of using fgf19 modulators
|
IN2014DN05885A
(ru)
|
2012-01-18 |
2015-06-05 |
Hoffmann La Roche |
|
RU2014133069A
(ru)
|
2012-02-11 |
2016-04-10 |
Дженентек, Инк. |
Транслокации r-спондина и способы с их использованием
|
EP2814587B1
(en)
|
2012-02-15 |
2018-05-02 |
F.Hoffmann-La Roche Ag |
Fc-receptor based affinity chromatography
|
JP2015514710A
(ja)
|
2012-03-27 |
2015-05-21 |
ジェネンテック, インコーポレイテッド |
Her3阻害剤に関する診断及び治療
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
KR20150006000A
(ko)
|
2012-05-01 |
2015-01-15 |
제넨테크, 인크. |
항-pmel17 항체 및 면역접합체
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
CN104335047B
(zh)
|
2012-05-23 |
2017-08-15 |
弗·哈夫曼-拉罗切有限公司 |
治疗剂的选择方法
|
US9738724B2
(en)
|
2012-06-08 |
2017-08-22 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
CA2875096A1
(en)
|
2012-06-15 |
2013-12-19 |
Genentech, Inc. |
Anti-pcsk9 antibodies, formulations, dosing, and methods of use
|
AR091476A1
(es)
|
2012-06-21 |
2015-02-04 |
Univ Indiana Res & Tech Corp |
POLIPEPTIDOS DE FUSION DE REGION Fc DE POLIPEPTIDO DE LIGANDO RECEPTOR DE INCRETINA Y CONJUGADOS CON FUNCION EFECTORA Fc ALTERADA
|
HUE029435T2
(en)
|
2012-07-04 |
2017-02-28 |
Hoffmann La Roche |
Anti-theophylline antibodies and methods of their application
|
EP3339328A1
(en)
|
2012-07-04 |
2018-06-27 |
F. Hoffmann-La Roche AG |
Anti-biotin antibodies and methods of use
|
EP3138580B1
(en)
|
2012-07-04 |
2021-03-03 |
F. Hoffmann-La Roche AG |
Covalently linked antigen-antibody conjugates
|
EP2870247B1
(en)
|
2012-07-05 |
2019-06-26 |
F.Hoffmann-La Roche Ag |
Expression and secretion system
|
US20140030281A1
(en)
|
2012-07-09 |
2014-01-30 |
Genentech, Inc. |
Anti-cd22 antibodies and immunoconjugates
|
AR091702A1
(es)
|
2012-07-09 |
2015-02-25 |
Genentech Inc |
Anticuerpos anti-cd79b e inmunoconjugados
|
SG11201500093TA
(en)
|
2012-07-09 |
2015-02-27 |
Genentech Inc |
Immunoconjugates comprising anti-cd79b antibodies
|
PE20150615A1
(es)
|
2012-07-09 |
2015-05-28 |
Genentech Inc |
Inmunoconjugados que comprenden un anticuerpo anti-cd22 ligado a una pirrolobenzodiazepina
|
ES2690312T3
(es)
|
2012-07-13 |
2018-11-20 |
Roche Glycart Ag |
Anticuerpos biespecíficos anti-VEGF/anti-ANG-2 y su uso en el tratamiento de enfermedades vasculares oculares
|
PL3434695T3
(pl)
|
2012-08-07 |
2021-05-17 |
Roche Glycart Ag |
Ulepszona immunoterapia
|
CN104540848B
(zh)
|
2012-08-08 |
2019-05-31 |
罗切格利卡特公司 |
白介素-10融合蛋白及其用途
|
EP2882775B1
(en)
|
2012-08-09 |
2018-02-14 |
Roche Glycart AG |
Asgpr antibodies and uses thereof
|
US20140044675A1
(en)
|
2012-08-10 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-2 fusion proteins and uses thereof
|
MY181648A
(en)
|
2012-08-24 |
2020-12-30 |
Univ California |
Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
|
EP2914621B1
(en)
|
2012-11-05 |
2023-06-07 |
Foundation Medicine, Inc. |
Novel ntrk1 fusion molecules and uses thereof
|
CA2884431A1
(en)
|
2012-11-08 |
2014-05-15 |
F. Hoffmann-La Roche Ag |
Her3 antigen binding proteins binding to the beta-hairpin of her3
|
BR112015010817A8
(pt)
|
2012-11-13 |
2018-01-23 |
Genentech Inc |
anticorpos anti-hemaglutinina isolado, método de tratamento, inibição ou prevenção de infecções, composição, composição farmacêutica, ácido nucleico isolado, célula hospedeira, método de produção de anticorpos e uso do anticorpo anti-hemaglutinina
|
ES2700984T3
(es)
|
2012-12-21 |
2019-02-20 |
Hoffmann La Roche |
Proteínas multifuncionales que comprenden MHC de clase I multivalente unida por disulfuro
|
WO2014107739A1
(en)
|
2013-01-07 |
2014-07-10 |
Eleven Biotherapeutics, Inc. |
Antibodies against pcsk9
|
US10980804B2
(en)
|
2013-01-18 |
2021-04-20 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
WO2014116749A1
(en)
|
2013-01-23 |
2014-07-31 |
Genentech, Inc. |
Anti-hcv antibodies and methods of using thereof
|
EP2958592A1
(en)
|
2013-02-22 |
2015-12-30 |
F. Hoffmann-La Roche AG |
Methods of treating cancer and preventing drug resistance
|
EP3708584A1
(en)
|
2013-02-26 |
2020-09-16 |
Roche Glycart AG |
Bispecific t cell activating antigen binding molecules
|
RU2015140921A
(ru)
|
2013-02-26 |
2017-04-03 |
Роше Гликарт Аг |
Антитела к mcsp
|
CA2896370A1
(en)
|
2013-02-26 |
2014-09-04 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
EP2961770A1
(en)
|
2013-02-26 |
2016-01-06 |
Roche Glycart AG |
Bispecific t cell activating antigen binding molecules
|
US9925240B2
(en)
|
2013-03-06 |
2018-03-27 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
JP6436965B2
(ja)
|
2013-03-14 |
2018-12-12 |
ジェネンテック, インコーポレイテッド |
抗b7−h4抗体及びイムノコンジュゲート
|
BR112015022604A2
(pt)
|
2013-03-14 |
2017-10-24 |
Genentech Inc |
usos de um modulador de modificador de cromatina e um antagonista de egfr
|
US20140271634A1
(en)
|
2013-03-14 |
2014-09-18 |
The Regents Of The University Of California |
Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
|
WO2014144865A2
(en)
|
2013-03-15 |
2014-09-18 |
Genentech, Inc. |
Anti-crth2 antibodies and methods of use
|
SG11201507429TA
(en)
|
2013-03-15 |
2015-10-29 |
Genentech Inc |
Il-22 polypeptides and il-22 fc fusion proteins and methods of use
|
MX2015012872A
(es)
|
2013-03-15 |
2016-02-03 |
Ac Immune Sa |
Anticuerpos anti-tau y metodos de uso.
|
KR20150130451A
(ko)
|
2013-03-15 |
2015-11-23 |
제넨테크, 인크. |
암 치료 방법 및 항암제 내성 예방을 위한 방법
|
EP3633377A1
(en)
|
2013-03-15 |
2020-04-08 |
F. Hoffmann-La Roche AG |
Biomarkers and methods of treating pd-1 and pd-l1 related conditions
|
JP6527132B2
(ja)
|
2013-03-15 |
2019-06-05 |
ジェネンテック, インコーポレイテッド |
肝臓がんの診断及び治療のための組成物及び方法
|
CN105229032A
(zh)
*
|
2013-03-18 |
2016-01-06 |
比奥塞罗克斯产品公司 |
人源化抗cd134(ox40)抗体及其应用
|
KR20230109779A
(ko)
|
2013-03-27 |
2023-07-20 |
세다르스-신나이 메디칼 센터 |
Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한섬유증 및 염증의 완화 및 반전
|
UA118028C2
(uk)
|
2013-04-03 |
2018-11-12 |
Рош Глікарт Аг |
Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
|
ES2871383T3
(es)
|
2013-04-29 |
2021-10-28 |
Hoffmann La Roche |
Anticuerpos asimétricos modificados que se unen al receptor de Fc y procedimientos de uso
|
ES2746136T3
(es)
|
2013-04-29 |
2020-03-04 |
Hoffmann La Roche |
Anticuerpos modificados de unión a FcRn humano y procedimientos de uso
|
EP4324480A3
(en)
|
2013-05-20 |
2024-05-08 |
F. Hoffmann-La Roche AG |
Anti-transferrin receptor antibodies and methods of use
|
EP3019522B1
(en)
|
2013-07-10 |
2017-12-13 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
EP3022224A2
(en)
|
2013-07-18 |
2016-05-25 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
CN111518199A
(zh)
|
2013-07-18 |
2020-08-11 |
图鲁斯生物科学有限责任公司 |
具有超长互补决定区的人源化抗体
|
EP4105236A1
(en)
|
2013-07-19 |
2022-12-21 |
Cedars-Sinai Medical Center |
Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
|
CN105518027A
(zh)
|
2013-09-17 |
2016-04-20 |
豪夫迈·罗氏有限公司 |
使用抗lgr5抗体的方法
|
EP3049445A4
(en)
|
2013-09-24 |
2017-10-25 |
Medicenna Therapeutics, Inc. |
Interleukin-2 fusion proteins and uses thereof
|
BR112016006197B1
(pt)
|
2013-09-27 |
2023-04-11 |
Chugai Seiyaku Kabushiki Kaisha |
Método para produzir um anticorpo biespecífico de polipeptídeos
|
CN105612182B
(zh)
|
2013-10-11 |
2019-12-10 |
豪夫迈·罗氏有限公司 |
多特异性结构域交换共有可变轻链抗体
|
RU2016117978A
(ru)
|
2013-10-11 |
2017-11-17 |
Дженентек, Инк. |
Ингибиторы nsp4 и способы их применения
|
TWI658052B
(zh)
|
2013-10-18 |
2019-05-01 |
美商建南德克公司 |
抗-rspo抗體及使用方法
|
WO2015061441A1
(en)
|
2013-10-23 |
2015-04-30 |
Genentech, Inc. |
Methods of diagnosing and treating eosinophilic disorders
|
CN104623637A
(zh)
|
2013-11-07 |
2015-05-20 |
健能隆医药技术(上海)有限公司 |
Il-22二聚体在制备静脉注射药物中的应用
|
RU2697098C1
(ru)
|
2013-11-21 |
2019-08-12 |
Ф.Хоффманн-Ля Рош Аг |
Антитела к альфа-синуклеину и способы применения
|
TW201533060A
(zh)
|
2013-12-13 |
2015-09-01 |
Genentech Inc |
抗cd33抗體及免疫結合物
|
CN105899535A
(zh)
|
2013-12-17 |
2016-08-24 |
豪夫迈·罗氏有限公司 |
用pd-1轴结合拮抗剂和抗cd20抗体治疗癌症的方法
|
NZ720515A
(en)
|
2013-12-17 |
2022-12-23 |
Genentech Inc |
Methods of treating cancers using pd-1 axis binding antagonists and taxanes
|
CA3131724A1
(en)
|
2013-12-17 |
2015-06-25 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
MX2016007965A
(es)
|
2013-12-17 |
2016-10-28 |
Genentech Inc |
Terapia de combinacion que comprende agonistas de union a ox40 y antagonistas de union al eje pd-1.
|
CA2932958A1
(en)
|
2013-12-20 |
2015-06-25 |
F. Hoffmann-La Roche Ag |
Humanized anti-tau(ps422) antibodies and methods of use
|
TWI728373B
(zh)
|
2013-12-23 |
2021-05-21 |
美商建南德克公司 |
抗體及使用方法
|
BR112016013744B1
(pt)
|
2013-12-24 |
2022-08-30 |
Bristol-Myers Squibb Company |
Compostos tricíclicos e seu uso como agentes anticâncer
|
CA2930046A1
(en)
|
2014-01-03 |
2015-07-09 |
F. Hoffmann-La Roche Ag |
Covalently linked polypeptide toxin-antibody conjugates
|
JP6602304B2
(ja)
|
2014-01-03 |
2019-11-06 |
エフ.ホフマン−ラ ロシュ アーゲー |
共有結合で連結されたヘリカー−抗ヘリカー抗体コンジュゲートおよびその用途
|
EP3089996B1
(en)
|
2014-01-03 |
2021-07-28 |
F. Hoffmann-La Roche AG |
Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
|
BR112016015589A2
(pt)
|
2014-01-06 |
2017-10-31 |
Hoffmann La Roche |
módulos de trânsito monovalentes para a barreira hematoencefálica
|
EP3835318A1
(en)
|
2014-01-15 |
2021-06-16 |
F. Hoffmann-La Roche AG |
Fc-region variants with modified fcrn- and maintained protein a-binding properties
|
KR20160111469A
(ko)
|
2014-01-24 |
2016-09-26 |
제넨테크, 인크. |
항-steap1 항체 및 면역접합체를 사용하는 방법
|
JOP20200094A1
(ar)
*
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
BR112016018288A2
(pt)
|
2014-02-06 |
2017-10-10 |
Hoffmann La Roche |
proteínas de fusão de interleucina 2 e uso das mesmas
|
CA2938466C
(en)
|
2014-02-08 |
2021-11-02 |
Genentech, Inc. |
Methods of treating alzheimer's disease
|
TWI785472B
(zh)
|
2014-02-08 |
2022-12-01 |
美商建南德克公司 |
治療阿茲海默症之方法
|
WO2015123325A1
(en)
|
2014-02-12 |
2015-08-20 |
Genentech, Inc. |
Anti-jagged1 antibodies and methods of use
|
BR112016018980A2
(pt)
|
2014-02-21 |
2017-10-10 |
Genentech Inc |
método de tratamento de um distúrbio, anticorpo multiespecífico, ácido nucleico isolado, célula hospedeira, métodos de produzir um anticorpo, de produção de uma metade de anticorpo ou de um anticorpo multiespecífico e de produção de um anticorpo multiespecífico, imunoconjugado e formulação farmacêutica
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
WO2015140591A1
(en)
|
2014-03-21 |
2015-09-24 |
Nordlandssykehuset Hf |
Anti-cd14 antibodies and uses thereof
|
JP6588461B2
(ja)
|
2014-03-31 |
2019-10-09 |
ジェネンテック, インコーポレイテッド |
抗血管新生剤及びox40結合アゴニストを含む併用療法
|
CR20160500A
(es)
|
2014-03-31 |
2016-12-14 |
Genentech Inc |
Anticuerpos anti-ox40 y métodos de uso
|
MX2016013635A
(es)
|
2014-04-18 |
2017-02-02 |
Acceleron Pharma Inc |
Métodos para aumentar los niveles de eritrocitos y tratar de la enfermedad de células falciformes.
|
CA2946398A1
(en)
|
2014-04-24 |
2015-10-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Superagonists, partial agonists and antagonists of interleukin-2
|
WO2015164615A1
(en)
|
2014-04-24 |
2015-10-29 |
University Of Oslo |
Anti-gluten antibodies and uses thereof
|
RU2016150370A
(ru)
|
2014-05-22 |
2018-06-26 |
Дженентек, Инк. |
Антитела и иммуноконъюгаты против GPC3
|
CA2944717A1
(en)
|
2014-05-23 |
2015-11-26 |
Genentech, Inc. |
Mit biomarkers and methods using the same
|
EA037006B1
(ru)
|
2014-06-06 |
2021-01-26 |
Бристол-Майерс Сквибб Компани |
Антитела к индуцируемому глюкокортикоидами рецептору фактора некроза опухолей (gitr) и их применения
|
MX2016015610A
(es)
|
2014-06-06 |
2017-07-13 |
Flexus Biosciences Inc |
Agentes inmunorreguladores.
|
EP3155015A1
(en)
|
2014-06-11 |
2017-04-19 |
F. Hoffmann-La Roche AG |
Anti-lgr5 antibodies and uses thereof
|
WO2015192111A1
(en)
|
2014-06-13 |
2015-12-17 |
Acceleron Pharma, Inc. |
Methods and compositions for treating ulcers
|
EP3154589A1
(en)
|
2014-06-13 |
2017-04-19 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
AR100978A1
(es)
|
2014-06-26 |
2016-11-16 |
Hoffmann La Roche |
LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
|
JP6654581B2
(ja)
|
2014-06-26 |
2020-02-26 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
抗brdu抗体および使用方法
|
JP2017165652A
(ja)
*
|
2014-06-30 |
2017-09-21 |
国立大学法人東北大学 |
新規抗ヒトox40リガンド抗体、及びこれを含む抗インフルエンザ薬
|
DK3309174T3
(da)
|
2014-07-11 |
2022-06-07 |
Ventana Med Syst Inc |
ANTI-PD-L1-antistoffer og diagnostiske anvendelser deraf
|
KR20170029490A
(ko)
|
2014-07-11 |
2017-03-15 |
제넨테크, 인크. |
노치 경로 억제
|
ES2753551T3
(es)
|
2014-07-22 |
2020-04-13 |
Sutro Biopharma Inc |
Anticuerpos anti-cd74, composiciones que comprenden anticuerpos anti-CD74 y procedimientos de uso de los anticuerpos anti-CD74
|
WO2016022468A1
(en)
|
2014-08-04 |
2016-02-11 |
Baylor Research Institute |
Antagonistic anti-ox40l antibodies and methods of their use
|
BR112016030462A2
(pt)
|
2014-08-04 |
2018-01-16 |
F. Hoffmann-La Roche Ag |
moléculas de ligação, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método de produção de uma molécula de ligação, composição farmacêutica, uso da molécula de ligação, método de tratamento de doenças e de indução da lise de células alvo
|
AU2015308818B2
(en)
|
2014-08-28 |
2021-02-25 |
Bioatla Llc |
Conditionally active chimeric antigen receptors for modified T-cells
|
TW201625689A
(zh)
|
2014-09-12 |
2016-07-16 |
建南德克公司 |
抗-b7-h4抗體及免疫結合物
|
AR101846A1
(es)
|
2014-09-12 |
2017-01-18 |
Genentech Inc |
Anticuerpos anti-cll-1 e inmunoconjugados
|
SI3191135T1
(sl)
|
2014-09-12 |
2021-01-29 |
Genentech, Inc. |
Anti-HER2 protitelesa in imunokonjugati
|
CN107108724A
(zh)
|
2014-09-12 |
2017-08-29 |
豪夫迈·罗氏有限公司 |
半胱氨酸改造抗体和缀合物
|
MX2017003472A
(es)
|
2014-09-17 |
2017-10-31 |
Genentech Inc |
Inmunoconjugados que comprenden anticuerpos anti-her2.
|
US20160082120A1
(en)
|
2014-09-23 |
2016-03-24 |
Genentech, Inc. |
METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES
|
JP2017536102A
(ja)
|
2014-10-16 |
2017-12-07 |
ジェネンテック, インコーポレイテッド |
抗アルファ−シヌクレイン抗体及び使用方法
|
JP2017536842A
(ja)
|
2014-11-03 |
2017-12-14 |
ジェネンテック, インコーポレイテッド |
Ox40アゴニスト治療薬の有効性及び評価を予測するための方法及びバイオマーカー
|
US20160161485A1
(en)
|
2014-11-03 |
2016-06-09 |
Genentech, Inc. |
Assays for detecting t cell immune subsets and methods of use thereof
|
AR102537A1
(es)
|
2014-11-05 |
2017-03-08 |
Flexus Biosciences Inc |
Agentes inmunomoduladores
|
UY36390A
(es)
|
2014-11-05 |
2016-06-01 |
Flexus Biosciences Inc |
Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
|
BR112017008809A2
(pt)
|
2014-11-05 |
2017-12-19 |
Flexus Biosciences Inc |
agentes imunorreguladores
|
MX2017005925A
(es)
|
2014-11-05 |
2017-11-08 |
Genentech Inc |
Metodos de producción de proteínas de cadena doble en bacterias.
|
CN108064308B
(zh)
|
2014-11-05 |
2023-06-09 |
豪夫迈·罗氏有限公司 |
细菌中产生双链蛋白的方法
|
CN107073126A
(zh)
|
2014-11-06 |
2017-08-18 |
豪夫迈·罗氏有限公司 |
包含ox40结合激动剂和tigit抑制剂的组合疗法
|
CA2960569A1
(en)
|
2014-11-06 |
2016-05-12 |
F. Hoffmann-Laroche Ag |
Fc-region variants with modified fcrn- and protein a-binding properties
|
HUE045466T2
(hu)
|
2014-11-06 |
2019-12-30 |
Hoffmann La Roche |
Fc-régió-variánsok módosított FcRn-kötéssel és alkalmazási eljárások
|
WO2016073157A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Anti-ang2 antibodies and methods of use thereof
|
EP3217787B1
(en)
|
2014-11-10 |
2019-04-17 |
F.Hoffmann-La Roche Ag |
Animal model for nephropathy and agents for treating the same
|
CR20170240A
(es)
|
2014-11-10 |
2018-04-03 |
Genentech Inc |
Anticuerpos anti-interleucina-33 y sus usos
|
MX2020012798A
(es)
|
2014-11-14 |
2022-04-07 |
Hoffmann La Roche |
Moléculas de unión a antígeno que comprenden un trímero de ligando de la familia de tnf.
|
BR112017010198A2
(pt)
|
2014-11-17 |
2017-12-26 |
Genentech Inc |
terapia de combinação compreendendo agonistas de ligação a ox40 e antagonistas de ligação ao eixo de pd-1
|
JP6859259B2
(ja)
|
2014-11-19 |
2021-04-14 |
ジェネンテック, インコーポレイテッド |
BACElに対する抗体及び神経疾患免疫療法のためのその使用
|
EP3221362B1
(en)
|
2014-11-19 |
2019-07-24 |
F.Hoffmann-La Roche Ag |
Anti-transferrin receptor antibodies and methods of use
|
US11008403B2
(en)
|
2014-11-19 |
2021-05-18 |
Genentech, Inc. |
Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use
|
LT3221357T
(lt)
|
2014-11-20 |
2020-08-25 |
F. Hoffmann-La Roche Ag |
Bendros lengvosios grandinės ir naudojimo būdai
|
WO2016079050A1
(en)
|
2014-11-20 |
2016-05-26 |
F. Hoffmann-La Roche Ag |
Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists
|
CN107001474B
(zh)
|
2014-11-21 |
2021-10-01 |
百时美施贵宝公司 |
抗cd73抗体及其用途
|
EP3227332B1
(en)
|
2014-12-03 |
2019-11-06 |
F.Hoffmann-La Roche Ag |
Multispecific antibodies
|
MA41119A
(fr)
|
2014-12-03 |
2017-10-10 |
Acceleron Pharma Inc |
Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
|
EA201790984A1
(ru)
|
2014-12-05 |
2018-05-31 |
Дженентек, Инк. |
Анти-cd79b антитела и способы их применения
|
JP2018502840A
(ja)
|
2014-12-10 |
2018-02-01 |
ジェネンテック, インコーポレイテッド |
血液脳関門受容体抗体及び使用方法
|
PL3233912T3
(pl)
|
2014-12-19 |
2021-12-27 |
Regenesance B.V. |
Przeciwciała, które wiążą ludzkie c6 oraz ich zastosowania
|
SG11201700841QA
(en)
|
2014-12-19 |
2017-03-30 |
Chugai Pharmaceutical Co Ltd |
Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
|
LT3233921T
(lt)
|
2014-12-19 |
2021-12-10 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-c5 antikūnai ir panaudojimo būdai
|
AR103232A1
(es)
|
2014-12-22 |
2017-04-26 |
Bristol Myers Squibb Co |
ANTAGONISTAS DE TGFbR
|
EP4249066A3
(en)
|
2014-12-23 |
2023-11-22 |
Bristol-Myers Squibb Company |
Antibodies to tigit
|
WO2016117346A1
(en)
|
2015-01-22 |
2016-07-28 |
Chugai Seiyaku Kabushiki Kaisha |
A combination of two or more anti-c5 antibodies and methods of use
|
MA41459A
(fr)
|
2015-02-03 |
2017-12-12 |
Als Therapy Development Inst |
Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
|
WO2016125495A1
(en)
|
2015-02-05 |
2016-08-11 |
Chugai Seiyaku Kabushiki Kaisha |
Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
|
WO2016127052A1
(en)
|
2015-02-05 |
2016-08-11 |
Bristol-Myers Squibb Company |
Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy
|
EA037112B1
(ru)
|
2015-03-02 |
2021-02-08 |
Ригель Фармасьютикалс, Инк. |
Ингибиторы tgf-
|
US9434785B1
(en)
|
2015-04-30 |
2016-09-06 |
Kymab Limited |
Anti-human OX40L antibodies and methods of treating graft versus host disease with the same
|
US9512229B2
(en)
|
2015-03-03 |
2016-12-06 |
Kymab Limited |
Synergistic combinations of OX40L antibodies for the treatment of GVHD
|
PT3265123T
(pt)
*
|
2015-03-03 |
2023-02-01 |
Kymab Ltd |
Anticorpos, usos e métodos
|
US9139653B1
(en)
|
2015-04-30 |
2015-09-22 |
Kymab Limited |
Anti-human OX40L antibodies and methods of treatment
|
MX2017011486A
(es)
|
2015-03-16 |
2018-06-15 |
Genentech Inc |
Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th2.
|
WO2016146833A1
(en)
|
2015-03-19 |
2016-09-22 |
F. Hoffmann-La Roche Ag |
Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
|
US11142587B2
(en)
|
2015-04-01 |
2021-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
Method for producing polypeptide hetero-oligomer
|
US20180208658A1
(en)
|
2015-04-03 |
2018-07-26 |
Eureka Therapeutics, Inc. |
Constructs targeting afp peptide/mhc complexes and uses thereof
|
JP2018516238A
(ja)
|
2015-04-03 |
2018-06-21 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
癌の治療のためのインドールアミン−2,3−ジオキシゲナーゼの阻害剤およびそれらの使用方法
|
MA41919A
(fr)
|
2015-04-06 |
2018-02-13 |
Acceleron Pharma Inc |
Hétéromultimères alk4:actriib et leurs utilisations
|
KR20180002659A
(ko)
|
2015-04-06 |
2018-01-08 |
악셀레론 파마 인코포레이티드 |
Tgf-베타 슈퍼패밀리 유형 i 및 유형 ii 수용체 이형다합체들과 이의 용도
|
JP6955445B2
(ja)
|
2015-04-07 |
2021-10-27 |
ジェネンテック, インコーポレイテッド |
アゴニスト性の活性を有する抗原結合複合体及びその使用方法
|
WO2016162505A1
(en)
|
2015-04-08 |
2016-10-13 |
F-Star Biotechnology Limited |
Her2 binding agent therapies
|
DK3283527T3
(da)
|
2015-04-13 |
2021-03-08 |
Five Prime Therapeutics Inc |
Kombinationsterapi mod cancer
|
KR20180012260A
(ko)
|
2015-04-17 |
2018-02-05 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
조율가능한 친화성을 갖는 면역조절 단백질
|
EP3913052A1
(en)
|
2015-04-24 |
2021-11-24 |
F. Hoffmann-La Roche AG |
Methods of identifying bacteria comprising binding polypeptides
|
EP3778640A1
(en)
|
2015-05-01 |
2021-02-17 |
Genentech, Inc. |
Masked anti-cd3 antibodies and methods of use
|
CN115109158A
(zh)
|
2015-05-07 |
2022-09-27 |
阿吉纳斯公司 |
抗ox40抗体及其使用方法
|
ES2815683T3
(es)
|
2015-05-11 |
2021-03-30 |
Bristol Myers Squibb Co |
Compuestos tricíclicos como agentes antineoplásicos
|
CN116196414A
(zh)
|
2015-05-11 |
2023-06-02 |
豪夫迈·罗氏有限公司 |
治疗狼疮性肾炎的组合物和方法
|
US9725449B2
(en)
|
2015-05-12 |
2017-08-08 |
Bristol-Myers Squibb Company |
Tricyclic compounds as anticancer agents
|
WO2016183115A1
(en)
|
2015-05-12 |
2016-11-17 |
Bristol-Myers Squibb Company |
5h-pyrido[3,2-b]indole compounds as anticancer agents
|
EP3294770B2
(en)
|
2015-05-12 |
2024-03-20 |
F. Hoffmann-La Roche AG |
Therapeutic and diagnostic methods for cancer
|
EP3302563A1
(en)
|
2015-05-29 |
2018-04-11 |
H. Hoffnabb-La Roche Ag |
Humanized anti-ebola virus glycoprotein antibodies and methods of use
|
IL255372B
(en)
|
2015-05-29 |
2022-07-01 |
Genentech Inc |
Therapeutic and diagnostic methods for cancer
|
CN107810012A
(zh)
|
2015-06-02 |
2018-03-16 |
豪夫迈·罗氏有限公司 |
使用抗il‑34抗体治疗神经疾病的组合物和方法
|
AU2016270858B2
(en)
|
2015-06-05 |
2022-04-28 |
Ac Immune Sa |
Anti-Tau antibodies and methods of use
|
JP2018521019A
(ja)
|
2015-06-08 |
2018-08-02 |
ジェネンテック, インコーポレイテッド |
抗ox40抗体を使用して癌を治療する方法
|
CA2988420A1
(en)
|
2015-06-08 |
2016-12-15 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
|
US10017577B2
(en)
|
2015-06-15 |
2018-07-10 |
Genentech, Inc. |
Antibodies and immunoconjugates
|
AR105026A1
(es)
|
2015-06-16 |
2017-08-30 |
Genentech Inc |
ANTICUERPOS MADURADOS POR AFINIDAD Y HUMANIZADOS PARA FcRH5 Y MÉTODOS PARA SU USO
|
US10501545B2
(en)
|
2015-06-16 |
2019-12-10 |
Genentech, Inc. |
Anti-CLL-1 antibodies and methods of use
|
EP3310811B1
(en)
|
2015-06-16 |
2021-06-16 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
AU2016280070B2
(en)
|
2015-06-17 |
2022-09-15 |
Genentech, Inc. |
Methods of treating locally advanced or metastatic breast cancers using PD-1 axis binding antagonists and taxanes
|
CA2986592A1
(en)
|
2015-06-17 |
2016-12-22 |
Genentech, Inc. |
Anti-her2 antibodies and methods of use
|
CN107810196B
(zh)
|
2015-06-24 |
2021-11-05 |
豪夫迈·罗氏有限公司 |
人源化的抗-Tau(pS422)抗体和使用方法
|
WO2016207240A1
(en)
|
2015-06-24 |
2016-12-29 |
F. Hoffmann-La Roche Ag |
Anti-transferrin receptor antibodies with tailored affinity
|
KR20180021864A
(ko)
|
2015-06-29 |
2018-03-05 |
제넨테크, 인크. |
장기 이식에서 사용하기 위한 유형 ii 항-cd20 항체
|
MX2017016502A
(es)
|
2015-06-29 |
2018-03-12 |
Univ Rockefeller |
Anticuerpos contra cd40 con actividad agonista mejorada.
|
CA2990214A1
(en)
|
2015-06-29 |
2017-01-05 |
Spring Bioscience Corporation |
Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
|
US10399987B2
(en)
|
2015-07-28 |
2019-09-03 |
Bristol-Myer Squibb Company |
TGF beta receptor antagonists
|
CA2994413A1
(en)
|
2015-08-04 |
2017-02-09 |
Acceleron Pharma, Inc. |
Methods for treating myeloproliferative disorders
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
EP3341372A1
(en)
|
2015-08-25 |
2018-07-04 |
Bristol-Myers Squibb Company |
Tgf beta receptor antagonists
|
WO2017040342A1
(en)
|
2015-08-28 |
2017-03-09 |
Genentech, Inc. |
Anti-hypusine antibodies and uses thereof
|
IL258088B2
(en)
|
2015-09-18 |
2024-02-01 |
Chugai Pharmaceutical Co Ltd |
Antibodies that bind to IL-8 and their uses
|
JP6904947B2
(ja)
|
2015-09-22 |
2021-07-21 |
スプリング バイオサイエンス コーポレーション |
抗ox40抗体及びその診断用途
|
EP3353203A2
(en)
|
2015-09-23 |
2018-08-01 |
H. Hoffnabb-La Roche Ag |
Optimized variants of anti-vegf antibodies
|
EP3662930A1
(en)
|
2015-09-24 |
2020-06-10 |
AbVitro LLC |
Hiv antibody compositions and methods of use
|
WO2017053748A2
(en)
|
2015-09-25 |
2017-03-30 |
Genentech, Inc. |
Anti-tigit antibodies and methods of use
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
WO2017055392A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
|
CN108026177B
(zh)
|
2015-10-02 |
2021-11-26 |
豪夫迈·罗氏有限公司 |
双特异性抗cd19xcd3 t细胞活化性抗原结合分子
|
KR20180053752A
(ko)
*
|
2015-10-02 |
2018-05-23 |
심포젠 에이/에스 |
항-pd-1 항체 및 조성물
|
EP3150636A1
(en)
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Tetravalent multispecific antibodies
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
WO2017055385A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
|
US20180282410A1
(en)
|
2015-10-02 |
2018-10-04 |
Hoffmann-La Roche Inc. |
Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
|
EP3356409A2
(en)
|
2015-10-02 |
2018-08-08 |
H. Hoffnabb-La Roche Ag |
Bispecific t cell activating antigen binding molecules
|
AR106365A1
(es)
|
2015-10-02 |
2018-01-10 |
Hoffmann La Roche |
Moléculas biespecíficas de unión a antígeno activadoras de células t
|
US10526413B2
(en)
|
2015-10-02 |
2020-01-07 |
Hoffmann-La Roche Inc. |
Bispecific antibodies specific for OX40
|
US12030942B2
(en)
|
2015-10-02 |
2024-07-09 |
Les Laboratoires Servier |
Anti-PD-1 antibodies and compositions
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
WO2017055393A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
|
CA2990755A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffman-La Roche Ag |
Bispecific anti-ceaxcd3 t cell activating antigen binding molecules
|
JP6657392B2
(ja)
|
2015-10-02 |
2020-03-04 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性抗ヒトcd20/ヒトトランスフェリン受容体抗体及び使用方法
|
CN108137684B
(zh)
*
|
2015-10-15 |
2022-03-08 |
苏州丁孚靶点生物技术有限公司 |
抗ox40抗体及其应用
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
MA45326A
(fr)
|
2015-10-20 |
2018-08-29 |
Genentech Inc |
Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
|
EP3184547A1
(en)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg antibodies and methods of use
|
BR112018006562A2
(pt)
|
2015-10-29 |
2018-12-11 |
Hoffmann La Roche |
anticorpos, ácido nucleico, célula hospedeira, método para produzir um anticorpo, conjugado e uso de um anticorpo
|
CA3088612C
(en)
|
2015-10-30 |
2022-04-12 |
Genentech, Inc. |
Anti-htra1 antibodies and methods of use thereof
|
JP2018534930A
(ja)
|
2015-10-30 |
2018-11-29 |
ジェネンテック, インコーポレイテッド |
抗d因子抗体及びコンジュゲート
|
MX2018005517A
(es)
|
2015-11-02 |
2018-11-09 |
Five Prime Therapeutics Inc |
Polipeptidos del dominio extracelular de cd80 y su uso en el tratamiento del cancer.
|
CN108602884B
(zh)
|
2015-11-08 |
2024-06-25 |
豪夫迈·罗氏有限公司 |
筛选多特异性抗体的方法
|
WO2017087901A2
(en)
|
2015-11-19 |
2017-05-26 |
Sutro Biopharma, Inc. |
Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
|
MX2018006072A
(es)
|
2015-11-19 |
2018-08-01 |
Squibb Bristol Myers Co |
Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos.
|
SG10201913538VA
(en)
|
2015-11-23 |
2020-02-27 |
Five Prime Therapeutics Inc |
Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
|
AU2016359695A1
(en)
|
2015-11-23 |
2018-06-14 |
Acceleron Pharma Inc. |
Methods for treating eye disorders
|
AU2016364889B2
(en)
|
2015-12-02 |
2024-01-04 |
Agenus Inc. |
Antibodies and methods of use thereof
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
CA2997406C
(en)
|
2015-12-09 |
2024-05-28 |
F. Hoffmann-La Roche Ag |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies or cytokine release
|
EP3390406A1
(en)
|
2015-12-15 |
2018-10-24 |
Bristol-Myers Squibb Company |
Cxcr4 receptor antagonists
|
EA036756B1
(ru)
|
2015-12-18 |
2020-12-16 |
Чугаи Сейяку Кабусики Кайся |
Антитела к с5 и способы их применения
|
BR112018009312A8
(pt)
|
2015-12-28 |
2019-02-26 |
Chugai Pharmaceutical Co Ltd |
método para promover eficiência de purificação de polipeptídeo contendo região de fc
|
AU2017205089B2
(en)
|
2016-01-08 |
2023-10-05 |
F. Hoffmann-La Roche Ag |
Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies
|
WO2017127764A1
(en)
|
2016-01-20 |
2017-07-27 |
Genentech, Inc. |
High dose treatments for alzheimer's disease
|
CN109069664B
(zh)
|
2016-01-27 |
2022-05-13 |
苏特罗生物制药公司 |
抗cd74抗体偶联物,包含抗cd74抗体偶联物的组合物以及抗cd74抗体偶联物的使用方法
|
JP6821693B2
(ja)
|
2016-02-29 |
2021-01-27 |
ジェネンテック, インコーポレイテッド |
がんのための治療方法及び診断方法
|
EP3423494A1
(en)
|
2016-03-04 |
2019-01-09 |
Bristol-Myers Squibb Company |
Combination therapy with anti-cd73 antibodies
|
US11767362B1
(en)
|
2016-03-15 |
2023-09-26 |
Chugai Seiyaku Kabushiki Kaisha |
Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodies
|
KR20220153109A
(ko)
|
2016-03-17 |
2022-11-17 |
세다르스-신나이 메디칼 센터 |
Rnaset2를 통한 염증성 장 질환의 진단 방법
|
KR102444614B1
(ko)
|
2016-03-22 |
2022-09-21 |
에프. 호프만-라 로슈 아게 |
프로테아제-활성화된 t 세포 이중특이적 분자
|
EP4273551A3
(en)
|
2016-03-25 |
2024-01-17 |
F. Hoffmann-La Roche AG |
Multiplexed total antibody and antibody-conjugated drug quantification assay
|
EP3443004A1
(en)
|
2016-04-14 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
Anti-rspo3 antibodies and methods of use
|
SG11201808783XA
(en)
|
2016-04-15 |
2018-11-29 |
Alpine Immune Sciences Inc |
Cd80 variant immunomodulatory proteins and uses thereof
|
CN109328069B
(zh)
|
2016-04-15 |
2023-09-01 |
亿一生物医药开发(上海)有限公司 |
Il-22在治疗坏死性小肠结肠炎中的用途
|
MX2018012492A
(es)
|
2016-04-15 |
2019-06-06 |
Genentech Inc |
Métodos para monitorear y tratar el cáncer.
|
WO2017180842A1
(en)
|
2016-04-15 |
2017-10-19 |
Bioatla, Llc |
Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof
|
KR20190003957A
(ko)
|
2016-04-15 |
2019-01-10 |
제넨테크, 인크. |
암 모니터링 및 치료 방법
|
JP7058609B2
(ja)
|
2016-04-15 |
2022-04-22 |
アルパイン イミューン サイエンシズ インコーポレイテッド |
Icosリガンドバリアント免疫調節タンパク質およびその使用
|
CA3021328A1
(en)
|
2016-04-18 |
2017-10-26 |
Celldex Therapeutics, Inc. |
Agonistic antibodies that bind human cd40 and uses thereof
|
CR20180509A
(es)
|
2016-05-02 |
2019-02-15 |
Hoffmann La Roche |
Contorsbody - un ligante de diana monocatenario
|
KR20190003686A
(ko)
|
2016-05-04 |
2019-01-09 |
브리스톨-마이어스 스큅 컴퍼니 |
인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
|
KR20190004742A
(ko)
|
2016-05-04 |
2019-01-14 |
브리스톨-마이어스 스큅 컴퍼니 |
인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
|
KR20190003685A
(ko)
|
2016-05-04 |
2019-01-09 |
브리스톨-마이어스 스큅 컴퍼니 |
인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
|
WO2017194442A1
(en)
|
2016-05-11 |
2017-11-16 |
F. Hoffmann-La Roche Ag |
Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety
|
EP3455252B1
(en)
|
2016-05-11 |
2022-02-23 |
F. Hoffmann-La Roche AG |
Modified anti-tenascin antibodies and methods of use
|
EP3243836A1
(en)
|
2016-05-11 |
2017-11-15 |
F. Hoffmann-La Roche AG |
C-terminally fused tnf family ligand trimer-containing antigen binding molecules
|
HRP20221298T1
(hr)
|
2016-05-13 |
2022-12-23 |
Bioatla, Inc. |
Anti-ror2 protutijela, fragmenti protutijela, njihovi imunokonjugati i njihove uporabe
|
EP3243832A1
(en)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
|
EP3458101B1
(en)
|
2016-05-20 |
2020-12-30 |
H. Hoffnabb-La Roche Ag |
Protac antibody conjugates and methods of use
|
WO2017205741A1
(en)
|
2016-05-27 |
2017-11-30 |
Genentech, Inc. |
Bioanalytical method for the characterization of site-specific antibody-drug conjugates
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
CN109476648B
(zh)
|
2016-06-06 |
2022-09-13 |
豪夫迈·罗氏有限公司 |
司维司群抗体-药物缀合物和使用方法
|
JP6815758B2
(ja)
*
|
2016-06-15 |
2021-01-20 |
キヤノン株式会社 |
電子写真感光体、電子写真感光体の製造方法、該電子写真感光体を有する電子写真装置およびプロセスカートリッジ
|
WO2017218698A1
(en)
|
2016-06-15 |
2017-12-21 |
Sutro Biopharma, Inc. |
Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
EP3475298A1
(en)
|
2016-06-24 |
2019-05-01 |
H. Hoffnabb-La Roche Ag |
Anti-polyubiquitin multispecific antibodies
|
WO2018005519A2
(en)
|
2016-06-27 |
2018-01-04 |
The Regents Of The University Of California |
Cancer treatment combinations
|
JP6983824B2
(ja)
|
2016-07-04 |
2021-12-17 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
新規抗体フォーマット
|
TWI780057B
(zh)
|
2016-07-14 |
2022-10-11 |
美商必治妥美雅史谷比公司 |
針對tim3之抗體及其用途
|
WO2018013936A1
(en)
|
2016-07-15 |
2018-01-18 |
Acceleron Pharma Inc. |
Compositions and methods for treating pulmonary hypertension
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
US20190292179A1
(en)
|
2016-07-21 |
2019-09-26 |
Bristol-Myers Squibb Company |
TGF Beta RECEPTOR ANTAGONISTS
|
FI3490582T3
(fi)
|
2016-07-27 |
2024-08-01 |
Acceleron Pharma Inc |
Koostumuksia käytettäväksi myelofibroosin hoitamisessa
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
WO2018022945A1
(en)
|
2016-07-28 |
2018-02-01 |
Alpine Immune Sciences, Inc. |
Cd112 variant immunomodulatory proteins and uses thereof
|
WO2018022946A1
(en)
|
2016-07-28 |
2018-02-01 |
Alpine Immune Sciences, Inc. |
Cd155 variant immunomodulatory proteins and uses thereof
|
CN117986372A
(zh)
|
2016-07-29 |
2024-05-07 |
中外制药株式会社 |
显示增加的备选fviii辅因子功能活性的双特异性抗体
|
WO2018027204A1
(en)
|
2016-08-05 |
2018-02-08 |
Genentech, Inc. |
Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
|
TWI693940B
(zh)
|
2016-08-05 |
2020-05-21 |
日商中外製藥股份有限公司 |
Il-8相關疾病之治療用或預防用組成物
|
CN109476748B
(zh)
|
2016-08-08 |
2023-05-23 |
豪夫迈·罗氏有限公司 |
用于癌症的治疗和诊断方法
|
EP3497128A2
(en)
|
2016-08-09 |
2019-06-19 |
Kymab Limited |
Anti-icos antibodies
|
EP3496763A1
(en)
|
2016-08-11 |
2019-06-19 |
Genentech, Inc. |
Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
|
KR20230145510A
(ko)
|
2016-08-17 |
2023-10-17 |
컴퓨젠 엘티디. |
항-tigit 항체, 항-pvrig 항체 및 이들의 조합
|
KR20190040990A
(ko)
|
2016-08-26 |
2019-04-19 |
브리스톨-마이어스 스큅 컴퍼니 |
인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
CN109689682B
(zh)
|
2016-09-19 |
2022-11-29 |
豪夫迈·罗氏有限公司 |
基于补体因子的亲和层析
|
CA3031589A1
(en)
|
2016-09-23 |
2018-03-29 |
Genentech, Inc. |
Uses of il-13 antagonists for treating atopic dermatitis
|
WO2018060301A1
(en)
|
2016-09-30 |
2018-04-05 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies against cd3
|
CN116650622A
(zh)
|
2016-10-05 |
2023-08-29 |
艾科赛扬制药股份有限公司 |
用于治疗肾脏疾病的组合物和方法
|
EP3522933B1
(en)
|
2016-10-05 |
2021-12-15 |
F. Hoffmann-La Roche AG |
Methods for preparing antibody drug conjugates
|
AU2017339517B2
(en)
|
2016-10-06 |
2024-03-14 |
Foundation Medicine, Inc. |
Therapeutic and diagnostic methods for cancer
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
EP3526254A1
(en)
|
2016-10-12 |
2019-08-21 |
Sutro Biopharma, Inc. |
Anti-folate receptor antibodies, compositions comprising anti-folate receptor antibodies and methods of making and using anti-folate receptor antibodies
|
CN109952370B
(zh)
|
2016-10-19 |
2023-09-08 |
豪夫迈·罗氏有限公司 |
用于产生免疫缀合物的方法
|
WO2018081074A1
(en)
|
2016-10-26 |
2018-05-03 |
Cedars-Sinai Medical Center |
Neutralizing anti-tl1a monoclonal antibodies
|
CN110267678A
(zh)
|
2016-10-29 |
2019-09-20 |
霍夫曼-拉罗奇有限公司 |
抗mic抗体和使用方法
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
MA46770A
(fr)
|
2016-11-09 |
2019-09-18 |
Agenus Inc |
Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
|
CN109923128A
(zh)
|
2016-11-15 |
2019-06-21 |
基因泰克公司 |
用于用抗cd20/抗cd3双特异性抗体进行治疗的给药
|
US10660909B2
(en)
|
2016-11-17 |
2020-05-26 |
Syntrix Biosystems Inc. |
Method for treating cancer using chemokine antagonists
|
EA201991214A1
(ru)
|
2016-11-18 |
2019-10-31 |
|
Антитела против pd-1 и их композиции
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
JOP20190100A1
(ar)
|
2016-11-19 |
2019-05-01 |
Potenza Therapeutics Inc |
بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
|
US11697680B2
(en)
|
2016-11-21 |
2023-07-11 |
Cureab Gmbh |
Anti-GP73 antibodies and immunoconjugates
|
UA128383C2
(uk)
|
2016-12-07 |
2024-07-03 |
Дженентек, Інк. |
Антитіло до тау-білка та спосіб його застосування
|
JP2020511937A
(ja)
|
2016-12-07 |
2020-04-23 |
ジェネンテック, インコーポレイテッド |
抗tau抗体及び使用方法
|
TW201827076A
(zh)
|
2016-12-12 |
2018-08-01 |
美商建南德克公司 |
使用抗pd-l1抗體及抗雄激素治療癌症之方法
|
EP3725809A1
(en)
|
2016-12-15 |
2020-10-21 |
AbbVie Biotherapeutics Inc. |
Anti-ox40 antibodies and their uses
|
CN110087682B
(zh)
|
2016-12-19 |
2023-12-15 |
豪夫迈·罗氏有限公司 |
用靶向性4-1bb(cd137)激动剂的组合疗法
|
CA3039446A1
(en)
|
2016-12-20 |
2018-06-28 |
F. Hoffmann-La Roche Ag |
Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists
|
CA3044920C
(en)
|
2016-12-21 |
2022-06-28 |
Roberto Falkenstein |
In vitro glycoengineering of antibodies
|
EP3559250A1
(en)
|
2016-12-21 |
2019-10-30 |
H. Hoffnabb-La Roche Ag |
Re-use of enzymes in in vitro glycoengineering of antibodies
|
EP3559249A1
(en)
|
2016-12-21 |
2019-10-30 |
H. Hoffnabb-La Roche Ag |
Method for in vitro glycoengineering of antibodies
|
JOP20190134A1
(ar)
|
2016-12-23 |
2019-06-02 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
|
WO2018132279A1
(en)
|
2017-01-05 |
2018-07-19 |
Bristol-Myers Squibb Company |
Tgf beta receptor antagonists
|
US11274157B2
(en)
|
2017-01-12 |
2022-03-15 |
Eureka Therapeutics, Inc. |
Constructs targeting histone H3 peptide/MHC complexes and uses thereof
|
AU2018210272C1
(en)
|
2017-01-20 |
2024-05-23 |
Arcus Biosciences, Inc. |
Azolopyrimidine for the treatment of cancer-related disorders
|
US20190367599A1
(en)
|
2017-01-31 |
2019-12-05 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
|
WO2018148224A1
(en)
|
2017-02-07 |
2018-08-16 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Phospholipid ether (ple) car t cell tumor targeting (ctct) agents
|
TWI778018B
(zh)
|
2017-02-10 |
2022-09-21 |
美商建南德克公司 |
抗類胰蛋白酶抗體、其組合物及其用途
|
WO2018156777A1
(en)
|
2017-02-22 |
2018-08-30 |
Sutro Biopharma, Inc. |
Pd-1/tim-3 bi-specific antibodies, compositions thereof, and methods of making and using the same
|
JP7178355B2
(ja)
|
2017-02-28 |
2022-11-25 |
エンドサイト・インコーポレイテッド |
Car t細胞療法のための組成物および方法
|
AU2018228873A1
(en)
|
2017-03-01 |
2019-08-29 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
NZ756132A
(en)
|
2017-03-10 |
2022-02-25 |
Hoffmann La Roche |
Method for producing multispecific antibodies
|
CA3053812A1
(en)
|
2017-03-16 |
2018-09-20 |
Alpine Immune Sciences, Inc. |
Pd-l2 variant immunomodulatory proteins and uses thereof
|
AU2018235838B2
(en)
|
2017-03-16 |
2023-12-14 |
Alpine Immune Sciences, Inc. |
CD80 variant immunomodulatory proteins and uses thereof
|
PT3596116T
(pt)
|
2017-03-16 |
2023-12-04 |
Alpine Immune Sciences Inc |
Proteínas imunomoduladoras de pd-l1 variante e suas utilizações
|
BR112019019706A2
(pt)
|
2017-03-22 |
2020-04-28 |
Genentech Inc |
conjugado de anticorpo, anticorpo, composição farmacêutica, métodos para reduzir ou inibir angiogênese e para tratar um distúrbio ocular
|
CA3056837A1
(en)
|
2017-03-27 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Improved antigen binding receptors
|
MA48996A
(fr)
|
2017-03-28 |
2020-02-05 |
Genentech Inc |
Méthodes de traitement de maladies neurodégénératives
|
JOP20190203A1
(ar)
|
2017-03-30 |
2019-09-03 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
|
JP2020512357A
(ja)
|
2017-03-31 |
2020-04-23 |
ファイブ プライム セラピューティクス, インコーポレイテッド |
抗gitr抗体を使用した癌の併用療法
|
EP3606947B1
(en)
|
2017-04-03 |
2022-12-21 |
F. Hoffmann-La Roche AG |
Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
|
SG11201909218RA
(en)
|
2017-04-03 |
2019-11-28 |
Hoffmann La Roche |
Antibodies binding to steap-1
|
MA49033B1
(fr)
|
2017-04-03 |
2022-10-31 |
Hoffmann La Roche |
Immunoconjugué d'un anticorps contre pd-1 avec il-2 mutée ou avec il-15
|
KR20220083863A
(ko)
|
2017-04-05 |
2022-06-20 |
심포젠 에이/에스 |
Pd-1, tim-3 및 lag-3을 표적화하는 조합 요법
|
TWI707871B
(zh)
|
2017-04-05 |
2020-10-21 |
瑞士商赫孚孟拉羅股份公司 |
抗lag3抗體
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
CN110770255A
(zh)
|
2017-04-11 |
2020-02-07 |
印希彼有限公司 |
具有受限cd3结合的多特异性多肽构建体及其使用方法
|
CN110505883A
(zh)
|
2017-04-13 |
2019-11-26 |
豪夫迈·罗氏有限公司 |
供治疗癌症的方法中使用的白介素-2免疫缀合物,cd40激动剂,和任选地pd-1轴结合拮抗剂
|
JP2020516253A
(ja)
|
2017-04-14 |
2020-06-11 |
ジェネンテック, インコーポレイテッド |
がんのための診断及び治療方法
|
AU2018256459B2
(en)
|
2017-04-21 |
2023-12-07 |
Ikena Oncology, Inc. |
Indole AHR inhibitors and uses thereof
|
AU2018254586A1
(en)
|
2017-04-21 |
2019-10-17 |
Genentech, Inc. |
Use of KLK5 antagonists for treatment of a disease
|
EP3615574A4
(en)
|
2017-04-26 |
2021-02-24 |
Eureka Therapeutics, Inc. |
CONSTRUCTIONS SPECIFICALLY RECOGNIZING GLYPICANE 3 AND USES OF SUCH LATEST
|
CA3059468A1
(en)
|
2017-04-27 |
2018-11-01 |
Tesaro, Inc. |
Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
|
AU2018258661A1
(en)
|
2017-04-28 |
2019-10-17 |
Five Prime Therapeutics, Inc. |
Methods of treatment with CD80 extracellular domain polypeptides
|
WO2018209049A1
(en)
|
2017-05-12 |
2018-11-15 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
PL3634417T3
(pl)
|
2017-05-17 |
2023-09-25 |
Arcus Biosciences, Inc. |
Pochodne chinazolino-pirazolowe do leczenia chorób związanych z nowotworem
|
AU2018269498A1
(en)
|
2017-05-18 |
2019-10-24 |
F. Hoffmann-La Roche Ag |
Reduction of application-related side reaction of a therapeutic antibody
|
KR20200010294A
(ko)
*
|
2017-05-24 |
2020-01-30 |
에이엘에스 테라피 디벨럽먼트 인스티튜트 |
치료용 항-cd40 리간드 항체
|
WO2018217944A1
(en)
|
2017-05-24 |
2018-11-29 |
Sutro Biopharma, Inc. |
Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same
|
MX2019014265A
(es)
|
2017-06-01 |
2020-08-03 |
Compugen Ltd |
Tratamientos conjuntos triples con anticuerpos.
|
JP2020521791A
(ja)
|
2017-06-02 |
2020-07-27 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療のためのii型抗cd20抗体及び抗cd20/cd30二重特異性抗体
|
US11542312B2
(en)
|
2017-06-19 |
2023-01-03 |
Medicenna Therapeutics, Inc. |
IL-2 superagonists in combination with anti-PD-1 antibodies
|
GB201709808D0
(en)
|
2017-06-20 |
2017-08-02 |
Kymab Ltd |
Antibodies
|
US20210087286A1
(en)
|
2017-06-20 |
2021-03-25 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
|
CA3066789A1
(en)
|
2017-06-30 |
2019-01-03 |
Bristol-Myers Squibb Company |
Amorphous and crystalline forms of ido inhibitors
|
KR20200093518A
(ko)
|
2017-07-21 |
2020-08-05 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
ES2963157T3
(es)
|
2017-07-26 |
2024-03-25 |
Forty Seven Inc |
Anticuerpos anti-SIRP-alfa y métodos relacionados
|
JP2020528061A
(ja)
|
2017-07-26 |
2020-09-17 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
BET阻害剤、Bcl−2阻害剤及び抗CD20抗体を用いた併用療法
|
EP3658588A1
(en)
|
2017-07-26 |
2020-06-03 |
Sutro Biopharma, Inc. |
Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
|
WO2019023459A1
(en)
|
2017-07-28 |
2019-01-31 |
Bristol-Myers Squibb Company |
CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
|
WO2019025811A1
(en)
|
2017-08-04 |
2019-02-07 |
Bicycletx Limited |
SPECIFIC BICYCLIC PEPTIDE LIGANDS OF CD137
|
AU2018316343A1
(en)
|
2017-08-11 |
2020-02-13 |
Genentech, Inc. |
Anti-CD8 antibodies and uses thereof
|
CA3073051A1
(en)
|
2017-08-17 |
2019-02-21 |
Ikena Oncology, Inc. |
Ahr inhibitors and uses thereof
|
JP7316263B2
(ja)
|
2017-08-31 |
2023-07-27 |
ブリストル-マイヤーズ スクイブ カンパニー |
抗癌剤としての環状ジヌクレオチド
|
EP3676279B1
(en)
|
2017-08-31 |
2021-12-01 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
EP3676278B1
(en)
|
2017-08-31 |
2023-04-12 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
WO2019055909A1
(en)
|
2017-09-18 |
2019-03-21 |
Sutro Biopharma, Inc. |
ALPHA ANTI-FOLATE ANTIBODY-RECEPTOR CONJUGATES AND USES THEREOF
|
WO2019059411A1
(en)
|
2017-09-20 |
2019-03-28 |
Chugai Seiyaku Kabushiki Kaisha |
DOSAGE FOR POLYTHERAPY USING PD-1 AXIS BINDING ANTAGONISTS AND GPC3 TARGETING AGENT
|
IL295603B2
(en)
|
2017-09-22 |
2024-03-01 |
Kymera Therapeutics Inc |
Protein compounds and their uses
|
WO2019060693A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES THEREOF
|
AU2018338859A1
(en)
|
2017-09-29 |
2020-02-06 |
Chugai Seiyaku Kabushiki Kaisha |
Multispecific antigen-binding molecule having blood coagulation factor VIII (FVIII) cofactor function-substituting activity, and pharmaceutical formulation containing said molecule as active ingredient
|
US11203592B2
(en)
|
2017-10-09 |
2021-12-21 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
WO2019074822A1
(en)
|
2017-10-09 |
2019-04-18 |
Bristol-Myers Squibb Company |
INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
|
KR20200061399A
(ko)
|
2017-10-10 |
2020-06-02 |
브리스톨-마이어스 스큅 컴퍼니 |
항암제로서의 시클릭 디뉴클레오티드
|
MA50360A
(fr)
|
2017-10-10 |
2020-08-19 |
Alpine Immune Sciences Inc |
Protéines immunomodulatrices de variants de ctla-4 et leurs utilisations
|
CA3185107A1
(en)
|
2017-10-12 |
2019-04-18 |
Immunowake Inc. |
Vegfr-antibody light chain fusion protein
|
CN111630069B
(zh)
*
|
2017-10-13 |
2024-05-31 |
勃林格殷格翰国际有限公司 |
针对Thomsen-nouvelle(Tn)抗原的人抗体
|
CN111406063B
(zh)
|
2017-10-16 |
2023-09-15 |
百时美施贵宝公司 |
作为抗癌剂的环二核苷酸
|
MA50404A
(fr)
|
2017-10-18 |
2020-08-26 |
Alpine Immune Sciences Inc |
Protéines immunomodulatrices à variants de ligand de icos variant, compositions et méthodes associées
|
BR112020007154A2
(pt)
|
2017-10-20 |
2020-09-29 |
F. Hoffmann-La Roche Ag |
método para produzir um polipeptídeo e polipeptídeos heterodimérico
|
CA3078676A1
(en)
|
2017-10-30 |
2019-05-09 |
F. Hoffmann-La Roche Ag |
Method for in vivo generation of multispecific antibodies from monospecific antibodies
|
EP3704155A2
(en)
|
2017-11-01 |
2020-09-09 |
F. Hoffmann-La Roche AG |
Combination therapy with targeted ox40 agonists
|
WO2019086394A1
(en)
|
2017-11-01 |
2019-05-09 |
F. Hoffmann-La Roche Ag |
The compbody - a multivalent target binder
|
WO2019086395A1
(en)
|
2017-11-01 |
2019-05-09 |
F. Hoffmann-La Roche Ag |
Trifab-contorsbody
|
KR20200079492A
(ko)
|
2017-11-01 |
2020-07-03 |
에프. 호프만-라 로슈 아게 |
이중특이성 2+1 컨터체
|
WO2019086499A1
(en)
|
2017-11-01 |
2019-05-09 |
F. Hoffmann-La Roche Ag |
Novel tnf family ligand trimer-containing antigen binding molecules
|
KR20200085303A
(ko)
|
2017-11-06 |
2020-07-14 |
브리스톨-마이어스 스큅 컴퍼니 |
Hpk1 억제제로서 유용한 이소푸라논 화합물
|
KR20200075860A
(ko)
|
2017-11-06 |
2020-06-26 |
제넨테크, 인크. |
암의 진단 및 치료 방법
|
US11629189B2
(en)
|
2017-12-19 |
2023-04-18 |
Kymab Limited |
Bispecific antibody for ICOS and PD-L1
|
KR102575787B1
(ko)
|
2017-12-21 |
2023-09-08 |
에프. 호프만-라 로슈 아게 |
Hla-a2/wt1에 결합하는 항체
|
EP3728321A1
(en)
|
2017-12-22 |
2020-10-28 |
F. Hoffmann-La Roche AG |
Use of pilra binding agents for treatment of a disease
|
MX2020006812A
(es)
|
2017-12-26 |
2020-11-06 |
Kymera Therapeutics Inc |
Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
|
EP3732198A1
(en)
|
2017-12-27 |
2020-11-04 |
Bristol-Myers Squibb Company |
Anti-cd40 antibodies and uses thereof
|
WO2019129221A1
(en)
|
2017-12-28 |
2019-07-04 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against tigit
|
CN111542543B
(zh)
|
2017-12-28 |
2023-12-22 |
南京传奇生物科技有限公司 |
针对pd-l1的抗体及其变体
|
EP3731865A1
(en)
|
2017-12-29 |
2020-11-04 |
F. Hoffmann-La Roche AG |
Method for improving vegf-receptor blocking selectivity of an anti-vegf antibody
|
CA3087149A1
(en)
|
2018-01-03 |
2019-07-11 |
Alpine Immune Sciences, Inc. |
Multi-domain immunomodulatory proteins and methods of use thereof
|
WO2019134981A1
(en)
|
2018-01-05 |
2019-07-11 |
Ac Immune Sa |
Misfolded tdp-43 binding molecules
|
US11447449B2
(en)
|
2018-01-05 |
2022-09-20 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
US11512080B2
(en)
|
2018-01-12 |
2022-11-29 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
US20220089720A1
(en)
|
2018-01-12 |
2022-03-24 |
Bristol-Myers Squibb Company |
Antibodies against tim3 and uses thereof
|
EP3737666A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADANTS AND USES THEREOF
|
SG11202004233UA
(en)
|
2018-01-15 |
2020-06-29 |
Nanjing Legend Biotech Co Ltd |
Single-domain antibodies and variants thereof against pd-1
|
CA3088649A1
(en)
|
2018-01-16 |
2019-07-25 |
Lakepharma, Inc. |
Bispecific antibody that binds cd3 and another target
|
CN112055595A
(zh)
|
2018-01-22 |
2020-12-08 |
恩多塞特公司 |
Car t细胞的使用方法
|
AR114565A1
(es)
|
2018-01-26 |
2020-09-23 |
Genentech Inc |
Proteínas de fusión fc il-22 y métodos de uso
|
AU2019212703A1
(en)
|
2018-01-26 |
2020-08-13 |
Genentech, Inc. |
Compositions and methods of use
|
CN111867581B
(zh)
|
2018-01-29 |
2023-12-26 |
默克专利股份有限公司 |
Gcn2抑制剂及其用途
|
CN118005640A
(zh)
|
2018-01-29 |
2024-05-10 |
默克专利股份有限公司 |
Gcn2抑制剂及其用途
|
TWI732176B
(zh)
|
2018-02-01 |
2021-07-01 |
大陸商信達生物製藥(蘇州)有限公司 |
全人源的抗b細胞成熟抗原(bcma)單鏈抗體及其應用
|
CR20200391A
(es)
|
2018-02-08 |
2020-10-19 |
Genentech Inc |
Moléculas biespecíficas de unión al antígeno y métodos de uso
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
WO2019157358A1
(en)
|
2018-02-09 |
2019-08-15 |
Genentech, Inc. |
Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
|
US10519187B2
(en)
|
2018-02-13 |
2019-12-31 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
WO2019158645A1
(en)
|
2018-02-14 |
2019-08-22 |
Abba Therapeutics Ag |
Anti-human pd-l2 antibodies
|
EP3755364A1
(en)
|
2018-02-21 |
2020-12-30 |
F. Hoffmann-La Roche AG |
Dosing for treatment with il-22 fc fusion proteins
|
WO2019165315A1
(en)
|
2018-02-23 |
2019-08-29 |
Syntrix Biosystems Inc. |
Method for treating cancer using chemokine antagonists alone or in combination
|
MX2020008882A
(es)
|
2018-02-26 |
2021-01-08 |
Genentech Inc |
Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
|
KR20200130362A
(ko)
|
2018-03-08 |
2020-11-18 |
브리스톨-마이어스 스큅 컴퍼니 |
항암제로서의 시클릭 디뉴클레오티드
|
CA3092002A1
(en)
|
2018-03-13 |
2019-09-19 |
F. Hoffmann-La Roche Ag |
Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies
|
TWI841551B
(zh)
|
2018-03-13 |
2024-05-11 |
瑞士商赫孚孟拉羅股份公司 |
使用靶向4-1bb (cd137)之促效劑的組合療法
|
US20200040103A1
(en)
|
2018-03-14 |
2020-02-06 |
Genentech, Inc. |
Anti-klk5 antibodies and methods of use
|
TWI827585B
(zh)
|
2018-03-15 |
2024-01-01 |
日商中外製藥股份有限公司 |
對茲卡病毒具有交叉反應性的抗登革病毒抗體及其使用方法
|
PE20210290A1
(es)
|
2018-03-21 |
2021-02-11 |
Five Prime Therapeutics Inc |
ANTICUERPOS DE UNION A VISTA A pH ACIDO
|
EP3774901A1
(en)
|
2018-03-26 |
2021-02-17 |
Sutro Biopharma, Inc. |
Anti-bcma receptor antibodies, compositions comprising anti bcma receptor antibodies and methods of making and using anti-bcma antibodies
|
AU2019245243A1
(en)
|
2018-03-29 |
2020-09-03 |
Genentech, Inc |
Modulating lactogenic activity in mammalian cells
|
AU2019241350A1
(en)
|
2018-03-30 |
2020-07-30 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies against LAG-3 and uses thereof
|
TW202011029A
(zh)
|
2018-04-04 |
2020-03-16 |
美商建南德克公司 |
偵測及定量fgf21之方法
|
KR20210006913A
(ko)
|
2018-04-11 |
2021-01-19 |
인히브릭스, 인크. |
제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 관련된 방법 및 용도
|
AU2019252795A1
(en)
|
2018-04-12 |
2020-10-29 |
Bristol-Myers Squibb Company |
Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody
|
PE20210652A1
(es)
|
2018-04-13 |
2021-03-26 |
Hoffmann La Roche |
Moleculas de union a antigeno dirigidas a her2 que comprenden 4-1bbl
|
EP3781162A1
(en)
|
2018-04-16 |
2021-02-24 |
Arrys Therapeutics, Inc. |
Ep4 inhibitors and use thereof
|
AR115052A1
(es)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
Anticuerpos multiespecíficos y utilización de los mismos
|
EP3784699A4
(en)
|
2018-04-25 |
2022-04-13 |
Prometheus Biosciences, Inc. |
OPTIMIZED ANTI-TL1A ANTIBODIES
|
US12037323B2
(en)
|
2018-05-03 |
2024-07-16 |
Bristol-Myers Squibb Company |
Uracil derivatives as Mer-AXL inhibitors
|
KR102227155B1
(ko)
*
|
2018-05-29 |
2021-03-12 |
주식회사 박셀바이오 |
Ox40l을 발현하는 배양보조세포 및 이를 이용한 자연살해세포 배양 방법
|
WO2019231243A1
(ko)
*
|
2018-05-29 |
2019-12-05 |
사회복지법인 삼성생명공익재단 |
Ox40l을 발현하는 배양보조세포 및 이를 이용한 자연살해세포 배양 방법
|
WO2019228514A1
(en)
|
2018-06-01 |
2019-12-05 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
Compositions and uses thereof for treating disease or condition
|
US20210238308A1
(en)
|
2018-06-04 |
2021-08-05 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule showing changed half-life in cytoplasm
|
CN112243444A
(zh)
|
2018-06-08 |
2021-01-19 |
豪夫迈·罗氏有限公司 |
具有减少的翻译后修饰的肽接头
|
WO2019241758A1
(en)
|
2018-06-15 |
2019-12-19 |
Alpine Immune Sciences, Inc. |
Pd-1 variant immunomodulatory proteins and uses thereof
|
CN112469440A
(zh)
|
2018-06-18 |
2021-03-09 |
优瑞科生物技术公司 |
靶向前列腺特异性膜抗原(psma)的构建体和其用途
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
CA3103017A1
(en)
|
2018-06-23 |
2019-12-26 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
SI3814348T1
(sl)
|
2018-06-27 |
2023-10-30 |
Bristol-Myers Squibb Company |
Substituirane naftiridinonske spojine, uporabne kot aktivatorji t celic
|
ES2950007T3
(es)
|
2018-06-27 |
2023-10-04 |
Bristol Myers Squibb Co |
Compuestos de naftiridinona útiles como activadores de células T
|
WO2020010177A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Tricyclic crbn ligands and uses thereof
|
CA3104530A1
(en)
|
2018-07-09 |
2020-01-16 |
Five Prime Therapeutics, Inc. |
Antibodies binding to ilt4
|
TW202028235A
(zh)
|
2018-07-11 |
2020-08-01 |
美商戊瑞治療有限公司 |
於酸性ph結合至含免疫球蛋白v域之t細胞活化抑制子(vista)之抗體
|
WO2020018789A1
(en)
|
2018-07-18 |
2020-01-23 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
|
KR20210033503A
(ko)
|
2018-07-18 |
2021-03-26 |
아르커스 바이오사이언시즈 인코포레이티드 |
아졸로피리미딘 화합물의 고체 형태
|
AU2019306628A1
(en)
|
2018-07-20 |
2021-02-11 |
Surface Oncology, LLC |
Anti-CD112R compositions and methods
|
US20210355113A1
(en)
|
2018-07-23 |
2021-11-18 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
US12059420B2
(en)
|
2018-07-23 |
2024-08-13 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
EP3827019A1
(en)
|
2018-07-24 |
2021-06-02 |
Inhibrx, Inc. |
Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
|
KR20210038642A
(ko)
|
2018-07-27 |
2021-04-07 |
아르커스 바이오사이언시즈 인코포레이티드 |
피리돈 a2r 길항제
|
BR112021001655A2
(pt)
|
2018-08-01 |
2021-05-04 |
Chugai Seiyaku Kabushiki Kaisha |
composição farmacêutica para uso no tratamento ou prevenção de uma doença relacionada a c5 e método para tratar ou prevenir uma doença relacionada a c5
|
BR112021001693A2
(pt)
|
2018-08-03 |
2021-05-04 |
Chugai Seiyaku Kabushiki Kaisha |
molécula de ligação ao antígeno contendo dois domínios de ligação ao antígeno q ligados entre si
|
CA3108369A1
(en)
|
2018-08-10 |
2020-02-13 |
Tomoyuki Igawa |
Anti-cd137 antigen-binding molecule and utilization thereof
|
TW202021618A
(zh)
|
2018-08-17 |
2020-06-16 |
美商23與我有限公司 |
抗il1rap抗體及其使用方法
|
US11253525B2
(en)
|
2018-08-29 |
2022-02-22 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
US10959986B2
(en)
|
2018-08-29 |
2021-03-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
JP2022500499A
(ja)
|
2018-09-07 |
2022-01-04 |
ピク セラピューティクス, インコーポレイテッド |
Eif4e阻害剤およびその使用
|
WO2020060944A1
(en)
|
2018-09-17 |
2020-03-26 |
Sutro Biopharma, Inc. |
Combination therapies with anti-folate receptor antibody conjugates
|
MA53651A
(fr)
|
2018-09-19 |
2021-07-28 |
Alpine Immune Sciences Inc |
Méthodes et utilisations de protéines de fusion de variant cd80 et constructions associées
|
WO2020061060A1
(en)
|
2018-09-19 |
2020-03-26 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
EP3857230B1
(en)
|
2018-09-21 |
2023-06-07 |
F. Hoffmann-La Roche AG |
Diagnostic methods for triple-negative breast cancer
|
PE20211767A1
(es)
|
2018-09-27 |
2021-09-07 |
Tizona Therapeutics |
Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y metodos de uso de anticuerpos anti-hla-g
|
US20210355216A1
(en)
|
2018-10-05 |
2021-11-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Methods and systems for controlling the agonistic properties of antibody variable domains by light
|
TW202021986A
(zh)
|
2018-10-11 |
2020-06-16 |
美商英伊布里克斯公司 |
5t4單域抗體及其治療性組合物
|
CA3115082A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
B7h3 single domain antibodies and therapeutic compositions thereof
|
EP3864045A2
(en)
|
2018-10-11 |
2021-08-18 |
Inhibrx, Inc. |
Dll3 single domain antibodies and therapeutic compositions thereof
|
US11208485B2
(en)
|
2018-10-11 |
2021-12-28 |
Inhibrx, Inc. |
PD-1 single domain antibodies and therapeutic compositions thereof
|
WO2020081493A1
(en)
|
2018-10-16 |
2020-04-23 |
Molecular Templates, Inc. |
Pd-l1 binding proteins
|
CA3116324A1
(en)
|
2018-10-18 |
2020-04-23 |
Genentech, Inc. |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
JP2022506156A
(ja)
|
2018-11-05 |
2022-01-17 |
ジェネンテック, インコーポレイテッド |
原核宿主細胞における2鎖タンパク質の産生方法
|
CN113316590A
(zh)
|
2018-11-16 |
2021-08-27 |
百时美施贵宝公司 |
抗nkg2a抗体及其用途
|
BR112021009373A2
(pt)
|
2018-11-16 |
2021-08-17 |
Memorial Sloan Kettering Cancer Center |
anticorpos para mucina-16 e métodos de uso dos mesmos
|
AU2019389151A1
(en)
|
2018-11-30 |
2021-06-10 |
Alpine Immune Sciences, Inc. |
CD86 variant immunomodulatory proteins and uses thereof
|
AU2019389174A1
(en)
|
2018-11-30 |
2021-07-01 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
AU2019392711A1
(en)
|
2018-12-05 |
2021-05-20 |
Morphosys Ag |
Multispecific antigen-binding molecules
|
EP3891185A2
(en)
|
2018-12-05 |
2021-10-13 |
F. Hoffmann-La Roche AG |
Diagnostic methods and compositions for cancer immunotherapy
|
BR112021010908A2
(pt)
|
2018-12-06 |
2021-08-31 |
Genentech, Inc. |
Método para tratamento de linfoma difuso de grandes células b, kit e imunoconjugado
|
WO2020123275A1
(en)
|
2018-12-10 |
2020-06-18 |
Genentech, Inc. |
Photocrosslinking peptides for site specific conjugation to fc-containing proteins
|
AR117327A1
(es)
|
2018-12-20 |
2021-07-28 |
23Andme Inc |
Anticuerpos anti-cd96 y métodos de uso de estos
|
CN113227131A
(zh)
|
2018-12-20 |
2021-08-06 |
豪夫迈·罗氏有限公司 |
经修饰的抗体Fc及其使用方法
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
BR112021010374A2
(pt)
|
2018-12-21 |
2021-08-24 |
23Andme, Inc. |
Anticorpos anti-il-36 e métodos de uso dos mesmos
|
WO2020127619A1
(en)
|
2018-12-21 |
2020-06-25 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
SG11202106116QA
(en)
|
2018-12-21 |
2021-07-29 |
Genentech Inc |
Methods of producing polypeptides using a cell line resistant to apoptosis
|
AR117468A1
(es)
|
2018-12-21 |
2021-08-11 |
Hoffmann La Roche |
ANTICUERPO QUE SE UNE A VEGF Y A IL-1b Y MÉTODOS DE UTILIZACIÓN
|
JP2022514343A
(ja)
|
2018-12-21 |
2022-02-10 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
腫瘍標的化アゴニストcd28抗原結合分子
|
TW202030204A
(zh)
|
2018-12-21 |
2020-08-16 |
瑞士商赫孚孟拉羅股份公司 |
靶向腫瘤之超促效cd28抗原結合分子
|
WO2020141145A1
(en)
|
2018-12-30 |
2020-07-09 |
F. Hoffmann-La Roche Ag |
Anti-rabbit cd19 antibodies and methods of use
|
AU2020208193A1
(en)
|
2019-01-14 |
2021-07-29 |
BioNTech SE |
Methods of treating cancer with a PD-1 axis binding antagonist and an RNA vaccine
|
MX2021008621A
(es)
|
2019-01-22 |
2021-08-19 |
Genentech Inc |
Anticuerpos de inmunoglobulina a y metodos de produccion y uso.
|
CN113330027A
(zh)
|
2019-01-23 |
2021-08-31 |
豪夫迈·罗氏有限公司 |
在真核宿主细胞中产生多聚体蛋白质的方法
|
US20220089770A1
(en)
|
2019-01-24 |
2022-03-24 |
Chugai Seiyaku Kabushiki Kaisha |
Novel cancer antigens and antibodies of said antigens
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
US11767078B2
(en)
|
2019-02-05 |
2023-09-26 |
Sram Deutschland Gmbh |
Drive arrangement for a bicycle
|
EP3931220A1
(en)
|
2019-02-27 |
2022-01-05 |
F. Hoffmann-La Roche AG |
Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies
|
JP7402247B2
(ja)
|
2019-03-08 |
2023-12-20 |
ジェネンテック, インコーポレイテッド |
細胞外小胞の膜結合タンパク質を検出及び定量化するための方法
|
MA55296A
(fr)
|
2019-03-14 |
2022-03-23 |
Hoffmann La Roche |
Traitement du cancer avec des anticorps bispécifiques de her2xcd3 en combinaison avec un mab anti-her2
|
TW202041535A
(zh)
|
2019-03-14 |
2020-11-16 |
德商莫菲西斯公司 |
靶向C5aR的抗體
|
TW202102542A
(zh)
|
2019-03-19 |
2021-01-16 |
瓦爾希伯倫私人腫瘤研究基金會 |
用於治療癌症的聯合療法
|
JP2022528887A
(ja)
|
2019-04-02 |
2022-06-16 |
バイスクルテクス・リミテッド |
バイシクルトキシンコンジュゲートおよびその使用
|
MA55565A
(fr)
|
2019-04-05 |
2022-02-09 |
Kymera Therapeutics Inc |
Agents de dégradation de stat et leurs utilisations
|
CN113677403A
(zh)
|
2019-04-12 |
2021-11-19 |
豪夫迈·罗氏有限公司 |
包含脂质运载蛋白突变蛋白的双特异性抗原结合分子
|
MX2021012607A
(es)
|
2019-04-17 |
2022-03-11 |
Alpine Immune Sciences Inc |
Metodos y usos de proteinas de fusion de ligando icos (icosl) variante.
|
CN114364703A
(zh)
|
2019-04-19 |
2022-04-15 |
豪夫迈·罗氏有限公司 |
抗mertk抗体及它们的使用方法
|
US20220362394A1
(en)
|
2019-05-03 |
2022-11-17 |
Sutro Biopharma, Inc. |
Anti-bcma antibody conjugates
|
AU2020270376A1
(en)
|
2019-05-03 |
2021-10-07 |
Genentech, Inc. |
Methods of treating cancer with an anti-PD-L1 antibody
|
BR112021021728A2
(pt)
|
2019-05-03 |
2021-12-28 |
Celgene Corp |
Conjugado de anticorpo anti-bcma, composições que compreendem os mesmos e métodos para fazer e usar os mesmos
|
WO2020231766A1
(en)
|
2019-05-13 |
2020-11-19 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
WO2020231713A1
(en)
|
2019-05-13 |
2020-11-19 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
MX2021013825A
(es)
|
2019-05-14 |
2022-01-18 |
Genentech Inc |
Procedimientos de uso de inmunoconjugados anti-cd79b para tratar el linfoma folicular.
|
JP2022533432A
(ja)
|
2019-05-23 |
2022-07-22 |
エイシー イミューン ソシエテ アノニム |
抗tdp-43結合分子およびその使用
|
MX2021014441A
(es)
|
2019-05-31 |
2022-01-06 |
Ikena Oncology Inc |
Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
|
WO2020260329A1
(en)
|
2019-06-26 |
2020-12-30 |
F. Hoffmann-La Roche Ag |
Fusion of an antibody binding cea and 4-1bbl
|
JP2022538139A
(ja)
|
2019-07-02 |
2022-08-31 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
変異体インターロイキン-2及び抗cd8抗体を含む免疫複合体
|
AR119382A1
(es)
|
2019-07-12 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos de pre-direccionamiento y métodos de uso
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
CR20220019A
(es)
|
2019-07-31 |
2022-02-11 |
Hoffmann La Roche |
Anticuerpos que se fijan a gprc5d
|
EP4004045A1
(en)
|
2019-07-31 |
2022-06-01 |
F. Hoffmann-La Roche AG |
Antibodies binding to gprc5d
|
JP7437261B2
(ja)
|
2019-07-31 |
2024-02-22 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
抗c5抗体クロバリマブの使用によるc5関連疾患の治療または予防のための薬用量および投与レジメン
|
KR20240001329A
(ko)
|
2019-07-31 |
2024-01-03 |
에프. 호프만-라 로슈 아게 |
항-c5 항체 크로발리맙의 사용에 의한 c5-관련 질병의 치료 또는 예방을 위한 투여량 및 투여 섭생
|
AU2020325770B2
(en)
|
2019-08-06 |
2022-08-25 |
Aprinoia Therapeutics Limited |
Antibodies that bind to pathological tau species and uses thereof
|
WO2021026179A1
(en)
|
2019-08-06 |
2021-02-11 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
AR119821A1
(es)
|
2019-08-28 |
2022-01-12 |
Bristol Myers Squibb Co |
Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
|
CA3146616A1
(en)
|
2019-09-12 |
2021-03-18 |
Matthew Dominic CASCINO |
Compositions and methods of treating lupus nephritis
|
JP2022547719A
(ja)
|
2019-09-13 |
2022-11-15 |
ニンバス サターン, インコーポレイテッド |
Hpk1アンタゴニストおよびその使用
|
US20210130492A1
(en)
|
2019-09-18 |
2021-05-06 |
Genentech, Inc. |
Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
|
EP4031575A1
(en)
|
2019-09-19 |
2022-07-27 |
Bristol-Myers Squibb Company |
Antibodies binding to vista at acidic ph
|
EP4031580A1
(en)
|
2019-09-20 |
2022-07-27 |
F. Hoffmann-La Roche AG |
Dosing for anti-tryptase antibodies
|
US11760801B2
(en)
|
2019-09-27 |
2023-09-19 |
Janssen Biotech, Inc. |
Anti-CEACAM antibodies and uses thereof
|
PE20221110A1
(es)
|
2019-09-27 |
2022-07-11 |
Genentech Inc |
Administracion de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1
|
CN114650843A
(zh)
|
2019-10-04 |
2022-06-21 |
Tae生命科学有限责任公司 |
包括fc突变和位点特异性缀合性质的抗体组合物
|
CA3153880A1
(en)
|
2019-10-18 |
2020-06-09 |
Juana Elva HERNANDEZ MONTALVO |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
CN114901311A
(zh)
|
2019-10-24 |
2022-08-12 |
普罗米修斯生物科学公司 |
Tnf样配体1a(tl1a)的人源化抗体及其用途
|
CA3155922A1
(en)
|
2019-11-06 |
2021-05-14 |
Huang Huang |
Diagnostic and therapeutic methods for treatment of hematologic cancers
|
US11548870B2
(en)
|
2019-11-19 |
2023-01-10 |
Bristol-Myers Squibb Company |
Compounds useful as inhibitors of helios protein
|
BR112022009944A2
(pt)
|
2019-11-26 |
2022-08-09 |
Bristol Myers Squibb Co |
Sais / cocristais de (r)-n-(4-clorofenil)-2-((1s,4s)-4-(6-fluoroquinolin-4-il)ciclo-hexil)propanamida
|
AU2020394424A1
(en)
|
2019-11-26 |
2022-06-16 |
Ikena Oncology, Inc. |
Polymorphic carbazole derivatives and uses thereof
|
IL293423A
(en)
|
2019-12-13 |
2022-07-01 |
Genentech Inc |
Anti-ly6g6d antibodies and methods of use
|
KR20220145325A
(ko)
|
2019-12-17 |
2022-10-28 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Irak 분해제 및 이의 용도
|
US11591332B2
(en)
|
2019-12-17 |
2023-02-28 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
CR20220256A
(es)
|
2019-12-18 |
2022-08-31 |
Hoffmann La Roche |
Anticuerpos que se unen a hla-a2/mage-a4
|
EP4077363A1
(en)
|
2019-12-20 |
2022-10-26 |
F. Hoffmann-La Roche AG |
Il-37 fusion proteins and uses thereof
|
CA3163003A1
(en)
|
2019-12-23 |
2021-07-01 |
Upender Velaparthi |
Substituted heteroaryl compounds useful as t cell activators
|
JP2023508055A
(ja)
|
2019-12-23 |
2023-02-28 |
ブリストル-マイヤーズ スクイブ カンパニー |
T細胞アクティベーターとして有用な置換キノリノニルピペラジン化合物
|
KR20220120624A
(ko)
|
2019-12-23 |
2022-08-30 |
브리스톨-마이어스 스큅 컴퍼니 |
T 세포 활성화제로서 유용한 치환된 피페라진 유도체
|
CA3162502A1
(en)
|
2019-12-23 |
2021-07-01 |
Yi Zhang |
Smarca degraders and uses thereof
|
AR120823A1
(es)
|
2019-12-23 |
2022-03-23 |
Bristol Myers Squibb Co |
Compuestos bicíclicos sustituidos útiles como activadores de células t
|
CA3162985A1
(en)
|
2019-12-23 |
2021-07-01 |
Upender Velaparthi |
Substituted quinazolinyl compounds useful as t cell activators
|
US20230058982A1
(en)
|
2019-12-27 |
2023-02-23 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-ctla-4 antibody and use thereof
|
CN113045655A
(zh)
|
2019-12-27 |
2021-06-29 |
高诚生物医药(香港)有限公司 |
抗ox40抗体及其用途
|
CN114930170A
(zh)
|
2020-01-02 |
2022-08-19 |
豪夫迈·罗氏有限公司 |
用于测定脑中的治疗性抗体量的方法
|
BR112022011749A2
(pt)
|
2020-01-06 |
2022-08-30 |
Vaccinex Inc |
Anticorpos anti-ccr8 e seus usos
|
EP4087874A1
(en)
|
2020-01-06 |
2022-11-16 |
HiFiBiO (HK) Limited |
Anti-tnfr2 antibody and uses thereof
|
JP2023510429A
(ja)
|
2020-01-07 |
2023-03-13 |
ハイファイバイオ (エイチケー) リミテッド |
抗ガレクチン-9抗体およびその使用
|
JP2023509952A
(ja)
|
2020-01-09 |
2023-03-10 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
新規4-1bbl三量体含有抗原結合分子
|
CN110818795B
(zh)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
抗tigit抗体和使用方法
|
US11534441B2
(en)
|
2020-01-15 |
2022-12-27 |
Blueprint Medicines Corporation |
MAP4K1 inhibitors
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
AU2021213177A1
(en)
|
2020-01-29 |
2022-08-18 |
Inhibrx Biosciences, Inc. |
CD28 single domain antibodies and multivalent and multispecific constructs thereof
|
EP4096708A1
(en)
|
2020-01-31 |
2022-12-07 |
Genentech, Inc. |
Methods of inducing neoepitope-specific t cells with a pd-1 axis binding antagonist and an rna vaccine
|
TW202144395A
(zh)
|
2020-02-12 |
2021-12-01 |
日商中外製藥股份有限公司 |
用於癌症之治療的抗cd137抗原結合分子
|
EP4110826A4
(en)
|
2020-02-28 |
2024-08-14 |
Shanghai Henlius Biotech Inc |
ANTI-CD137 CONSTRUCTS, MULTISPECIFIC ANTIBODIES AND THEIR USES
|
AU2021225920A1
(en)
|
2020-02-28 |
2022-09-15 |
Shanghai Henlius Biotech, Inc. |
Anti-CD137 construct and use thereof
|
IL296139A
(en)
|
2020-03-03 |
2022-11-01 |
Pic Therapeutics Inc |
eif4e inhibitors and uses thereof
|
PE20230252A1
(es)
|
2020-03-13 |
2023-02-07 |
Genentech Inc |
Anticuerpos anti-interleucina-33 y sus usos de estos
|
JP2023518408A
(ja)
|
2020-03-19 |
2023-05-01 |
ジェネンテック, インコーポレイテッド |
アイソフォーム選択的抗tgf-ベータ抗体及び使用方法
|
CN115298165A
(zh)
|
2020-03-19 |
2022-11-04 |
艾库斯生物科学有限公司 |
作为HIF-2α抑制剂的四氢化萘和四氢喹啉化合物
|
IL296451A
(en)
|
2020-03-19 |
2022-11-01 |
Kymera Therapeutics Inc |
mdm2 joints and their uses
|
TW202140441A
(zh)
|
2020-03-23 |
2021-11-01 |
美商必治妥美雅史谷比公司 |
經取代之側氧基異吲哚啉化合物
|
MX2022011752A
(es)
|
2020-03-24 |
2022-10-18 |
Genentech Inc |
Agentes de fijacion a tie2 y metodos de uso.
|
CA3169908A1
(en)
|
2020-03-26 |
2021-09-30 |
Genentech, Inc. |
Modified mammalian cells having reduced host cell proteins
|
JP2023520414A
(ja)
|
2020-03-30 |
2023-05-17 |
エフ. ホフマン-ラ ロシュ アーゲー |
Vegf及びpdgf-bに結合する抗体及び使用方法
|
CN115698717A
(zh)
|
2020-04-03 |
2023-02-03 |
基因泰克公司 |
癌症的治疗和诊断方法
|
WO2021207662A1
(en)
|
2020-04-10 |
2021-10-14 |
Genentech, Inc. |
Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
|
MX2022012541A
(es)
|
2020-04-15 |
2022-11-07 |
Hoffmann La Roche |
Inmunoconjugados.
|
BR112022021441A2
(pt)
|
2020-04-24 |
2022-12-13 |
Genentech Inc |
Métodos para tratar linfoma folicular e linfoma difuso de grandes células b e kits
|
EP4143345A1
(en)
|
2020-04-28 |
2023-03-08 |
Genentech, Inc. |
Methods and compositions for non-small cell lung cancer immunotherapy
|
KR20230087414A
(ko)
|
2020-05-03 |
2023-06-16 |
레베나 (쑤저우) 바이오파마 컴퍼니 리미티드 |
항-Trop-2 항체를 포함하는 항체-약물 접합체 (ADCS), 상기 ADCS를 포함하는 조성물, 및 이의 제조 및 사용 방법
|
IL297980A
(en)
|
2020-05-08 |
2023-01-01 |
Alpine Immune Sciences Inc |
Immunomodulatory proteins that inhibit april and baff and methods of using them
|
US20230192867A1
(en)
|
2020-05-15 |
2023-06-22 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
WO2021238886A1
(en)
|
2020-05-27 |
2021-12-02 |
Staidson (Beijing) Biopharmaceuticals Co., Ltd. |
Antibodies specifically recognizing nerve growth factor and uses thereof
|
KR20230018425A
(ko)
|
2020-05-29 |
2023-02-07 |
23앤드미 인코포레이티드 |
항-cd200r1 항체 및 이의 사용 방법
|
CN115698068A
(zh)
|
2020-06-02 |
2023-02-03 |
艾库斯生物科学有限公司 |
抗tigit抗体
|
BR112022024629A2
(pt)
|
2020-06-02 |
2023-02-23 |
Dynamicure Biotechnology Llc |
Construtos anti-cd93 e seus usos
|
CN116529260A
(zh)
|
2020-06-02 |
2023-08-01 |
当康生物技术有限责任公司 |
抗cd93构建体及其用途
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
BR112022024996A2
(pt)
|
2020-06-08 |
2022-12-27 |
Hoffmann La Roche |
Anticorpos, ácido nucleico, célula hospedeira, método para produzir um anticorpo, composição farmacêutica, agente terapêutico, uso do anticorpo e método para tratar um indivíduo com hepatite b
|
CN115698719A
(zh)
|
2020-06-12 |
2023-02-03 |
基因泰克公司 |
用于癌症免疫疗法的方法和组合物
|
AU2021293038A1
(en)
|
2020-06-16 |
2023-02-02 |
F. Hoffmann-La Roche Ag |
Methods and compositions for treating triple-negative breast cancer
|
WO2021257124A1
(en)
|
2020-06-18 |
2021-12-23 |
Genentech, Inc. |
Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
|
TW202216767A
(zh)
|
2020-06-19 |
2022-05-01 |
瑞士商赫孚孟拉羅股份公司 |
與CD3及FolR1結合之抗體
|
WO2021258010A1
(en)
|
2020-06-19 |
2021-12-23 |
Gossamer Bio Services, Inc. |
Oxime compounds useful as t cell activators
|
JP2023530961A
(ja)
|
2020-06-19 |
2023-07-20 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Cd3に結合する抗体
|
KR20230025783A
(ko)
|
2020-06-19 |
2023-02-23 |
에프. 호프만-라 로슈 아게 |
면역 활성화 Fc 도메인 결합 분자
|
AR122659A1
(es)
|
2020-06-19 |
2022-09-28 |
Hoffmann La Roche |
Anticuerpos biespecíficos para linfocitos t activados por proteasa
|
TWI811703B
(zh)
|
2020-06-19 |
2023-08-11 |
瑞士商赫孚孟拉羅股份公司 |
與cd3及cd19結合之抗體
|
WO2021255146A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cea
|
US20230235040A1
(en)
|
2020-06-22 |
2023-07-27 |
Almirall, S.A. |
Anti-il-36 antibodies and methods of use thereof
|
BR112022025989A2
(pt)
|
2020-06-23 |
2023-01-17 |
Hoffmann La Roche |
Moléculas, um ou mais polinucleotídeos, um ou mais vetores, célula hospedeira, método para produzir uma molécula, composição farmacêutica, uso da molécula e método para tratar uma doença
|
MX2022016453A
(es)
|
2020-06-24 |
2023-02-01 |
Genentech Inc |
Lineas celulares resistentes a la apoptosis.
|
EP4172203A1
(en)
|
2020-06-25 |
2023-05-03 |
F. Hoffmann-La Roche AG |
Anti-cd3/anti-cd28 bispecific antigen binding molecules
|
CA3187277A1
(en)
|
2020-07-10 |
2022-01-13 |
F. Hoffmann-La Roche Ag |
Antibodies which bind to cancer cells and target radionuclides to said cells
|
AU2021308653A1
(en)
|
2020-07-17 |
2023-02-16 |
Genentech, Inc. |
Anti-Notch2 antibodies and methods of use
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
KR20230133832A
(ko)
|
2020-07-29 |
2023-09-19 |
다이내믹큐어 바이오테크놀로지 엘엘씨 |
항-cd93 구축물 및 그의 용도
|
BR112023001638A2
(pt)
|
2020-07-30 |
2023-02-23 |
Kymera Therapeutics Inc |
Métodos de tratamento de linfomas mutantes
|
JP2023536602A
(ja)
|
2020-08-03 |
2023-08-28 |
ジェネンテック, インコーポレイテッド |
リンパ腫のための診断及び治療方法
|
CN116234831A
(zh)
|
2020-08-03 |
2023-06-06 |
豪夫迈·罗氏有限公司 |
改善的抗原结合受体
|
AU2021325225A1
(en)
|
2020-08-10 |
2023-03-23 |
Gv20 Therapeutics Llc |
Compositions and methods for treating autoimmune diseases and cancers by targeting IGSF8
|
JP2023537761A
(ja)
|
2020-08-14 |
2023-09-05 |
エイシー イミューン ソシエテ アノニム |
ヒト化抗tdp-43結合分子およびその使用
|
JP2023538906A
(ja)
|
2020-08-17 |
2023-09-12 |
バイシクルティーエクス・リミテッド |
ネクチン-4に特異的な二環コンジュゲート及びその使用
|
EP4204448A2
(en)
|
2020-08-27 |
2023-07-05 |
cureab GmbH |
Anti-golph2 antibodies for macrophage and dendritic cell differentiation
|
WO2022047222A2
(en)
|
2020-08-28 |
2022-03-03 |
Genentech, Inc. |
Crispr/cas9 multiplex knockout of host cell proteins
|
WO2022049165A1
(en)
|
2020-09-04 |
2022-03-10 |
F. Hoffmann-La Roche Ag |
Antibody that binds to vegf-a and ang2 and methods of use
|
US11970539B2
(en)
|
2020-09-14 |
2024-04-30 |
Ichnos Sciences SA |
Antibodies that bind to IL1RAP and uses thereof
|
JP2023544407A
(ja)
|
2020-10-05 |
2023-10-23 |
ジェネンテック, インコーポレイテッド |
抗FcRH5/抗CD3二重特異性抗体による処置のための投与
|
WO2022081718A1
(en)
|
2020-10-14 |
2022-04-21 |
Five Prime Therapeutics, Inc. |
Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
|
AR123855A1
(es)
|
2020-10-20 |
2023-01-18 |
Genentech Inc |
Anticuerpos anti-mertk conjugados con peg y métodos de uso
|
JP2023547447A
(ja)
|
2020-10-28 |
2023-11-10 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
改良型抗原結合受容体
|
WO2022093981A1
(en)
|
2020-10-28 |
2022-05-05 |
Genentech, Inc. |
Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
|
IL302217A
(en)
|
2020-11-04 |
2023-06-01 |
Genentech Inc |
Dosage for treatment with bispecific anti-CD20/anti-CD3 antibodies and anti-CD79B drug antibody conjugates
|
EP4240766A2
(en)
|
2020-11-04 |
2023-09-13 |
Genentech, Inc. |
Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
|
JP7402381B2
(ja)
|
2020-11-04 |
2023-12-20 |
ジェネンテック, インコーポレイテッド |
抗cd20/抗cd3二重特異性抗体による処置のための投与
|
CN116472288A
(zh)
|
2020-11-06 |
2023-07-21 |
诺华股份有限公司 |
抗体Fc变体
|
WO2022101458A1
(en)
|
2020-11-16 |
2022-05-19 |
F. Hoffmann-La Roche Ag |
Combination therapy with fap-targeted cd40 agonists
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
EP4255895A1
(en)
|
2020-12-02 |
2023-10-11 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
AR124250A1
(es)
|
2020-12-07 |
2023-03-01 |
UCB Biopharma SRL |
Anticuerpos
|
WO2022122654A1
(en)
|
2020-12-07 |
2022-06-16 |
UCB Biopharma SRL |
Multi-specific antibodies and antibody combinations
|
EP4261222A1
(en)
|
2020-12-09 |
2023-10-18 |
HK inno.N Corporation |
ANTI-OX40L ANTIBODY, ANTI-OX40L/ANTI-TNFalpha BISPECIFIC ANTIBODY, AND USES THEREOF
|
AU2021400725A1
(en)
|
2020-12-16 |
2023-08-03 |
Gossamer Bio Services, Inc. |
Compounds useful as t cell activators
|
CR20230263A
(es)
|
2020-12-17 |
2023-08-21 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de estos
|
WO2022140797A1
(en)
|
2020-12-23 |
2022-06-30 |
Immunowake Inc. |
Immunocytokines and uses thereof
|
WO2022148853A1
(en)
|
2021-01-11 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
MX2023008193A
(es)
|
2021-01-11 |
2023-10-05 |
Bicycletx Ltd |
Procedimientos para tratar el cáncer.
|
WO2022152656A1
(en)
|
2021-01-12 |
2022-07-21 |
F. Hoffmann-La Roche Ag |
Split antibodies which bind to cancer cells and target radionuclides to said cells
|
KR20230131205A
(ko)
|
2021-01-13 |
2023-09-12 |
에프. 호프만-라 로슈 아게 |
병용 요법
|
US20230113202A1
(en)
|
2021-02-02 |
2023-04-13 |
Liminal Biosciences Limited |
Gpr84 antagonists and uses thereof
|
CN116888116A
(zh)
|
2021-02-02 |
2023-10-13 |
里米诺生物科学有限公司 |
Gpr84拮抗剂和其用途
|
WO2022169825A1
(en)
|
2021-02-03 |
2022-08-11 |
Mozart Therapeutics, Inc. |
Binding agents and methods of using the same
|
JP2024509695A
(ja)
|
2021-02-03 |
2024-03-05 |
ジェネンテック, インコーポレイテッド |
多重特異性結合タンパク質分解プラットフォームおよび使用方法
|
US20240109899A1
(en)
|
2021-02-04 |
2024-04-04 |
Bristol-Myers Squibb Company |
Benzofuran compounds as sting agonists
|
JP2024506339A
(ja)
|
2021-02-12 |
2024-02-13 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療のための二環式テトラヒドロアゼピン誘導体
|
IL304905A
(en)
|
2021-02-15 |
2023-10-01 |
Kymera Therapeutics Inc |
IRAK4 joints and their uses
|
JP2024509169A
(ja)
|
2021-03-03 |
2024-02-29 |
ソレント・セラピューティクス・インコーポレイテッド |
抗bcma抗体を含む抗体-薬物コンジュゲート
|
JP2024509191A
(ja)
|
2021-03-05 |
2024-02-29 |
ダイナミキュア バイオテクノロジー エルエルシー |
抗vista構築物およびその使用
|
WO2022187856A1
(en)
|
2021-03-05 |
2022-09-09 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
JP2024510176A
(ja)
|
2021-03-08 |
2024-03-06 |
ブループリント メディシンズ コーポレイション |
Map4k1阻害剤
|
AU2022232951A1
(en)
|
2021-03-10 |
2023-10-19 |
Immunowake Inc. |
Immunomodulatory molecules and uses thereof
|
AR125074A1
(es)
|
2021-03-12 |
2023-06-07 |
Genentech Inc |
Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso
|
US11918582B2
(en)
|
2021-03-15 |
2024-03-05 |
Rapt Therapeutics, Inc. |
Pyrazole pyrimidine compounds and uses thereof
|
JP2024511970A
(ja)
|
2021-03-15 |
2024-03-18 |
ジェネンテック, インコーポレイテッド |
ループス腎炎の治療の組成物及び方法
|
WO2022197877A1
(en)
|
2021-03-19 |
2022-09-22 |
Genentech, Inc. |
Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
|
TW202300648A
(zh)
|
2021-03-25 |
2023-01-01 |
美商當康生物科技有限公司 |
抗-igfbp7構築體及其用途
|
KR20230167067A
(ko)
|
2021-04-05 |
2023-12-07 |
브리스톨-마이어스 스큅 컴퍼니 |
암의 치료를 위한 피리디닐 치환된 옥소이소인돌린 화합물
|
TW202304881A
(zh)
|
2021-04-06 |
2023-02-01 |
美商必治妥美雅史谷比公司 |
經吡啶基取代之側氧基異吲哚啉化合物
|
CN117279664A
(zh)
|
2021-04-10 |
2023-12-22 |
普方生物制药美国公司 |
Folr1结合剂、其偶联物及其使用方法
|
AR125344A1
(es)
|
2021-04-15 |
2023-07-05 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-c1s
|
IL307673A
(en)
|
2021-04-16 |
2023-12-01 |
Ikena Oncology Inc |
MEK inhibitors and their use
|
EP4326855A1
(en)
|
2021-04-19 |
2024-02-28 |
Genentech, Inc. |
Modified mammalian cells
|
JP2024516631A
(ja)
|
2021-04-23 |
2024-04-16 |
プロファウンドバイオ ユーエス カンパニー |
抗cd70抗体、そのコンジュゲートおよびこれを使用する方法
|
CA3217865A1
(en)
|
2021-04-28 |
2022-11-03 |
Minotaur Therapeutics, Inc. |
Humanized chimeric bovine antibodies and methods of use
|
TW202244059A
(zh)
|
2021-04-30 |
2022-11-16 |
瑞士商赫孚孟拉羅股份公司 |
用抗cd20/抗cd3雙特異性抗體進行治療之給藥
|
EP4329818A1
(en)
|
2021-04-30 |
2024-03-06 |
Celgene Corporation |
Combination therapies using an anti-bcma antibody drug conjugate (adc) in combination with a gamma secretase inhibitor (gsi)
|
EP4330282A1
(en)
|
2021-04-30 |
2024-03-06 |
F. Hoffmann-La Roche AG |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
US20240254224A1
(en)
|
2021-05-03 |
2024-08-01 |
UCB Biopharma SRL |
Antibodies
|
EP4333869A1
(en)
|
2021-05-07 |
2024-03-13 |
Alpine Immune Sciences, Inc. |
Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein
|
CA3218170A1
(en)
|
2021-05-12 |
2022-11-17 |
Jamie Harue HIRATA |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
CN117396510A
(zh)
|
2021-05-14 |
2024-01-12 |
基因泰克公司 |
Trem2的激动剂
|
WO2022245978A1
(en)
|
2021-05-19 |
2022-11-24 |
Sutro Biopharma, Inc. |
Anti-folate receptor conjugate combination therapy with bevacizumab
|
TW202313603A
(zh)
|
2021-05-21 |
2023-04-01 |
美商阿克思生物科學有限公司 |
Axl抑制劑化合物
|
WO2022246177A1
(en)
|
2021-05-21 |
2022-11-24 |
Arcus Biosciences, Inc. |
Axl compounds
|
KR20240010469A
(ko)
|
2021-05-21 |
2024-01-23 |
제넨테크, 인크. |
관심 재조합 생성물의 생성을 위한 변형된 세포
|
AR126009A1
(es)
|
2021-06-02 |
2023-08-30 |
Hoffmann La Roche |
Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
|
TW202306994A
(zh)
|
2021-06-04 |
2023-02-16 |
日商中外製藥股份有限公司 |
抗ddr2抗體及其用途
|
US20240279334A1
(en)
|
2021-06-17 |
2024-08-22 |
Amberstone Biosciences, Inc. |
Anti-cd3 constructs and uses thereof
|
IL308633A
(en)
|
2021-06-25 |
2024-01-01 |
Chugai Pharmaceutical Co Ltd |
Use of anti-CTLA-4 antibodies
|
TW202317627A
(zh)
|
2021-06-25 |
2023-05-01 |
日商中外製藥股份有限公司 |
抗ctla-4抗體
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
TW202317633A
(zh)
|
2021-07-08 |
2023-05-01 |
美商舒泰神(加州)生物科技有限公司 |
特異性識別tnfr2的抗體及其用途
|
EP4370545A1
(en)
|
2021-07-12 |
2024-05-22 |
Genentech, Inc. |
Structures for reducing antibody-lipase binding
|
MX2024000751A
(es)
|
2021-07-14 |
2024-03-25 |
Blueprint Medicines Corp |
Compuestos heterociclicos como inhibidores de map4k1.
|
KR20240032889A
(ko)
|
2021-07-14 |
2024-03-12 |
제넨테크, 인크. |
항-c-c 모티프 케모카인 수용체 8(ccr8) 항체 및 사용 방법
|
WO2023284714A1
(zh)
|
2021-07-14 |
2023-01-19 |
舒泰神(北京)生物制药股份有限公司 |
特异性识别cd40的抗体及其应用
|
CN117940406A
(zh)
|
2021-07-15 |
2024-04-26 |
缆图药品公司 |
Map4k1抑制剂
|
EP4373859A1
(en)
|
2021-07-22 |
2024-05-29 |
F. Hoffmann-La Roche AG |
Heterodimeric fc domain antibodies
|
EP4373576A1
(en)
|
2021-07-22 |
2024-05-29 |
Genentech, Inc. |
Brain targeting compositions and methods of use thereof
|
CN117794953A
(zh)
|
2021-08-03 |
2024-03-29 |
豪夫迈·罗氏有限公司 |
双特异性抗体及使用方法
|
JP2024530189A
(ja)
|
2021-08-07 |
2024-08-16 |
ジェネンテック, インコーポレイテッド |
びまん性大細胞型b細胞リンパ腫を処置するために抗cd79bイムノコンジュゲートを使用する方法
|
WO2023019239A1
(en)
|
2021-08-13 |
2023-02-16 |
Genentech, Inc. |
Dosing for anti-tryptase antibodies
|
GB202111905D0
(en)
|
2021-08-19 |
2021-10-06 |
UCB Biopharma SRL |
Antibodies
|
EP4388014A1
(en)
|
2021-08-19 |
2024-06-26 |
F. Hoffmann-La Roche AG |
Multivalent anti-variant fc-region antibodies and methods of use
|
KR20240099138A
(ko)
|
2021-08-23 |
2024-06-28 |
이뮤니타스 테라퓨틱스, 인크. |
항-cd161 항체 및 그의 용도
|
CN118019739A
(zh)
|
2021-08-25 |
2024-05-10 |
皮克医疗公司 |
Eif4e抑制剂及其用途
|
WO2023028235A1
(en)
|
2021-08-25 |
2023-03-02 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
AU2022332303A1
(en)
|
2021-08-27 |
2024-02-01 |
Genentech, Inc. |
Methods of treating tau pathologies
|
TW202325727A
(zh)
|
2021-08-30 |
2023-07-01 |
美商建南德克公司 |
抗聚泛素多特異性抗體
|
WO2023056403A1
(en)
|
2021-09-30 |
2023-04-06 |
Genentech, Inc. |
Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
|
WO2023056069A1
(en)
|
2021-09-30 |
2023-04-06 |
Angiex, Inc. |
Degrader-antibody conjugates and methods of using same
|
WO2023062048A1
(en)
|
2021-10-14 |
2023-04-20 |
F. Hoffmann-La Roche Ag |
Alternative pd1-il7v immunoconjugates for the treatment of cancer
|
EP4416174A1
(en)
|
2021-10-14 |
2024-08-21 |
F. Hoffmann-La Roche AG |
New interleukin-7 immunoconjugates
|
WO2023064958A1
(en)
|
2021-10-15 |
2023-04-20 |
Compugen Ltd. |
Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies
|
WO2023076876A1
(en)
|
2021-10-26 |
2023-05-04 |
Mozart Therapeutics, Inc. |
Modulation of immune responses to viral vectors
|
WO2023073599A1
(en)
|
2021-10-28 |
2023-05-04 |
Novartis Ag |
Engineered fc variants
|
KR20240099315A
(ko)
|
2021-11-05 |
2024-06-28 |
아메리칸 다이어그노스틱스 앤드 테라피, 엘엘씨 (에이디엑스알엑스) |
암배아성 항원에 대한 단클론성 항체 및 이의 용도
|
WO2023086807A1
(en)
|
2021-11-10 |
2023-05-19 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
CA3236006A1
(en)
|
2021-11-16 |
2023-05-25 |
Genentech, Inc. |
Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab
|
AR127692A1
(es)
|
2021-11-16 |
2024-02-21 |
Ac Immune Sa |
Anticuerpos anti-asc para uso en tratamientos antiinflamatorios
|
CN118302443A
(zh)
|
2021-11-25 |
2024-07-05 |
豪夫迈·罗氏有限公司 |
改善的抗原结合受体
|
KR20240108799A
(ko)
|
2021-12-01 |
2024-07-09 |
서트로 바이오파마, 인크. |
항 엽산 수용체 접합체 암 요법
|
WO2023103788A1
(zh)
|
2021-12-06 |
2023-06-15 |
北京三诺佳邑生物技术有限责任公司 |
特异性结合肺炎克雷伯菌o2抗原和o1抗原的双特异性抗体以及组合物
|
AR127887A1
(es)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y plap
|
IL313169A
(en)
|
2021-12-15 |
2024-07-01 |
Genentech Inc |
Stabilized IL-18 polypeptides and their uses
|
AU2022411573A1
(en)
|
2021-12-17 |
2024-06-27 |
Shanghai Henlius Biologics Co., Ltd. |
Anti-ox40 antibodies and methods of use
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
KR20240116755A
(ko)
|
2021-12-17 |
2024-07-30 |
상하이 헨리우스 바이오테크, 인크. |
항-ox40 항체, 다중 특이적 항체 및 이의 사용 방법
|
WO2023122772A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Oxime derivatives useful as t cell activators
|
WO2023122778A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Pyridazinone derivatives useful as t cell activators
|
WO2023122777A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Oxime derivatives useful as t cell activators
|
AU2023206045A1
(en)
|
2022-01-07 |
2024-08-22 |
Johnson & Johnson Enterprise Innovation Inc. |
Materials and methods of il-1beta binding proteins
|
WO2023141445A1
(en)
|
2022-01-19 |
2023-07-27 |
Genentech, Inc. |
Anti-notch2 antibodies and conjugates and methods of use
|
WO2023150186A1
(en)
|
2022-02-01 |
2023-08-10 |
Arvinas Operations, Inc. |
Dgk targeting compounds and uses thereof
|
WO2023156549A1
(en)
|
2022-02-16 |
2023-08-24 |
Ac Immune Sa |
Humanized anti-tdp-43 binding molecules and uses thereof
|
WO2023172883A1
(en)
|
2022-03-07 |
2023-09-14 |
Alpine Immune Sciences, Inc. |
Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023173026A1
(en)
|
2022-03-10 |
2023-09-14 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
US20230414750A1
(en)
|
2022-03-23 |
2023-12-28 |
Hoffmann-La Roche Inc. |
Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
|
AR128876A1
(es)
|
2022-03-28 |
2024-06-19 |
Hoffmann La Roche |
Anticuerpos biespecíficos de linfocitos t activables con proteasa folr1 mejorados
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023194565A1
(en)
|
2022-04-08 |
2023-10-12 |
Ac Immune Sa |
Anti-tdp-43 binding molecules
|
WO2023201299A1
(en)
|
2022-04-13 |
2023-10-19 |
Genentech, Inc. |
Pharmaceutical compositions of therapeutic proteins and methods of use
|
WO2023198727A1
(en)
|
2022-04-13 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
|
WO2023198851A1
(en)
|
2022-04-14 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for controlling the tumor cell killing by light
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
AR129136A1
(es)
|
2022-04-26 |
2024-07-17 |
Novartis Ag |
Anticuerpos multiespecíficos que se dirigen a il-13 e il-18
|
WO2023215737A1
(en)
|
2022-05-03 |
2023-11-09 |
Genentech, Inc. |
Anti-ly6e antibodies, immunoconjugates, and uses thereof
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
TW202402810A
(zh)
|
2022-05-11 |
2024-01-16 |
瑞士商赫孚孟拉羅股份公司 |
與vegf—a及il6結合之抗體及其使用方法
|
WO2023230205A1
(en)
|
2022-05-25 |
2023-11-30 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2023239803A1
(en)
|
2022-06-08 |
2023-12-14 |
Angiex, Inc. |
Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same
|
US20240058465A1
(en)
|
2022-06-30 |
2024-02-22 |
Sutro Biopharma, Inc. |
Anti-ror1 antibody conjugates, compositions comprising anti ror1 antibody conjugates, and methods of making and using anti-ror1 antibody conjugates
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024020432A1
(en)
|
2022-07-19 |
2024-01-25 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
TW202417503A
(zh)
|
2022-07-19 |
2024-05-01 |
美商舒泰神(加州)生物科技有限公司 |
特異性識別b和t淋巴細胞衰減器(btla)的抗體及其應用
|
WO2024020564A1
(en)
|
2022-07-22 |
2024-01-25 |
Genentech, Inc. |
Anti-steap1 antigen-binding molecules and uses thereof
|
WO2024030856A2
(en)
|
2022-08-01 |
2024-02-08 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory proteins and related methods
|
WO2024028363A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
|
TW202415650A
(zh)
|
2022-08-02 |
2024-04-16 |
英商利米那生物科技有限公司 |
芳基-三唑基及相關gpr84拮抗劑及其用途
|
TW202416972A
(zh)
|
2022-08-02 |
2024-05-01 |
英商利米那生物科技有限公司 |
經取代之吡啶酮gpr84拮抗劑及其用途
|
WO2024030956A2
(en)
|
2022-08-03 |
2024-02-08 |
Mozart Therapeutics, Inc. |
Cd39-specific binding agents and methods of using the same
|
WO2024028731A1
(en)
|
2022-08-05 |
2024-02-08 |
Janssen Biotech, Inc. |
Transferrin receptor binding proteins for treating brain tumors
|
WO2024028732A1
(en)
|
2022-08-05 |
2024-02-08 |
Janssen Biotech, Inc. |
Cd98 binding constructs for treating brain tumors
|
WO2024036100A1
(en)
|
2022-08-08 |
2024-02-15 |
Bristol-Myers Squibb Company |
Substituted tetrazolyl compounds useful as t cell activators
|
WO2024036101A1
(en)
|
2022-08-09 |
2024-02-15 |
Bristol-Myers Squibb Company |
Tertiary amine substituted bicyclic compounds useful as t cell activators
|
TW202417001A
(zh)
|
2022-08-11 |
2024-05-01 |
瑞士商赫孚孟拉羅股份公司 |
雙環四氫吖呯衍生物
|
WO2024033389A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033388A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
TW202417439A
(zh)
|
2022-08-11 |
2024-05-01 |
瑞士商赫孚孟拉羅股份公司 |
雙環四氫噻吖呯衍生物
|
US20240092859A1
(en)
|
2022-08-18 |
2024-03-21 |
Immunocore Ltd |
T cell receptors and fusion proteins thereof
|
WO2024037633A2
(en)
|
2022-08-19 |
2024-02-22 |
Evive Biotechnology (Shanghai) Ltd |
Formulations comprising g-csf and uses thereof
|
WO2024049949A1
(en)
|
2022-09-01 |
2024-03-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
WO2024054929A1
(en)
|
2022-09-07 |
2024-03-14 |
Dynamicure Biotechnology Llc |
Anti-vista constructs and uses thereof
|
WO2024068572A1
(en)
|
2022-09-28 |
2024-04-04 |
F. Hoffmann-La Roche Ag |
Improved protease-activatable t cell bispecific antibodies
|
WO2024077018A2
(en)
|
2022-10-04 |
2024-04-11 |
Alpine Immune Sciences, Inc. |
Methods and uses of taci-fc fusion immunomodulatory protein
|
WO2024077118A2
(en)
|
2022-10-06 |
2024-04-11 |
Bicara Therapeutics Inc. |
Multispecific proteins and related methods
|
WO2024077239A1
(en)
|
2022-10-07 |
2024-04-11 |
Genentech, Inc. |
Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies
|
WO2024079009A1
(en)
|
2022-10-10 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Combination therapy of a gprc5d tcb and proteasome inhibitors
|
WO2024079015A1
(en)
|
2022-10-10 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Combination therapy of a gprc5d tcb and imids
|
WO2024079010A1
(en)
|
2022-10-10 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Combination therapy of a gprc5d tcb and cd38 antibodies
|
WO2024091991A1
(en)
|
2022-10-25 |
2024-05-02 |
Genentech, Inc. |
Therapeutic and diagnostic methods for multiple myeloma
|
WO2024094741A1
(en)
|
2022-11-03 |
2024-05-10 |
F. Hoffmann-La Roche Ag |
Combination therapy with anti-cd19/anti-cd28 bispecific antibody
|
WO2024102734A1
(en)
|
2022-11-08 |
2024-05-16 |
Genentech, Inc. |
Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
|
WO2024100170A1
(en)
|
2022-11-11 |
2024-05-16 |
F. Hoffmann-La Roche Ag |
Antibodies binding to hla-a*02/foxp3
|
WO2024104933A1
(en)
|
2022-11-15 |
2024-05-23 |
F. Hoffmann-La Roche Ag |
Antigen binding molecules
|
WO2024112894A1
(en)
|
2022-11-22 |
2024-05-30 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
WO2024137865A1
(en)
|
2022-12-22 |
2024-06-27 |
Gossamer Bio Services, Inc. |
Compounds useful as t cell activators
|
WO2024151515A2
(en)
|
2023-01-09 |
2024-07-18 |
Odyssey Therapeutics, Inc. |
Anti-tnfr2 antigen-binding proteins and uses thereof
|
WO2024155807A1
(en)
|
2023-01-18 |
2024-07-25 |
Genentech, Inc. |
Multispecific antibodies and uses thereof
|
WO2024153725A1
(en)
|
2023-01-20 |
2024-07-25 |
F. Hoffmann-La Roche Ag |
Recombinant fc domain - il2 variant polypeptides and combination therapy with membrane-anchored antigen binding polypeptides
|
WO2024156672A1
(en)
|
2023-01-25 |
2024-08-02 |
F. Hoffmann-La Roche Ag |
Antibodies binding to csf1r and cd3
|
US20240269263A1
(en)
|
2023-02-06 |
2024-08-15 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory compositions and related methods
|